Unum Group: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Oct 30, 2024 and accepted by EDGAR at Oct 30, 2024, 16:54 ET.
Management's discussion and analysis
As filed, 148,753 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
| Page | |
|---|---|
| Executive Summary | 88 |
| Reconciliation of Non-GAAP and Other Financial Measures | 93 |
| Critical Accounting Estimates | 95 |
| Accounting Developments | 95 |
| Consolidated Operating Results | 96 |
| Segment Results | 98 |
| Unum US Segment | 98 |
| Unum International Segment | 108 |
| Colonial Life Segment | 114 |
| Closed Block Segment | 117 |
| Corporate Segment | 120 |
| Investments | 121 |
| Liquidity and Capital Resources | 128 |
87
Executive Summary
Unum Group, a Delaware general business corporation, and its insurance and non-insurance subsidiaries, which collectively with Unum Group we refer to as the Company, operate in the United States, the United Kingdom, Poland, and, to a limited extent, in certain other countries. The principal operating subsidiaries in the United States are Unum Life Insurance Company of America (Unum America), Provident Life and Accident Insurance Company, The Paul Revere Life Insurance Company, Colonial Life & Accident Insurance Company, Unum Insurance Company, Starmount Life Insurance Company, in the United Kingdom, Unum Limited, and in Poland, Unum Zycie TUiR S.A. (Unum Poland). We are a leading provider of financial protection benefits in the United States and the United Kingdom. Our products include disability, life, accident, critical illness, dental and vision, and other related services. We market our products primarily through the workplace.
We have three principal operating business segments: Unum US, Unum International, and Colonial Life. Our other segments are the Closed Block and Corporate segments. These segments are discussed more fully under "Segment Results" included herein in this Item 2.
The benefits we provide help the working world thrive throughout life's moments and protect people from the financial hardship of illness, injury, or loss of life. As a leading provider of employee benefits, we offer a broad portfolio of products and services through the workplace that provide support when it is needed most.
Specifically, we offer group, individual, voluntary, and dental and vision products as well as provide certain fee-based services. These products and services, which can be sold stand-alone or combined with other coverages, help employers of all sizes attract and retain the talented and capable workforce they need to succeed while protecting the incomes and livelihood of their employees. We believe employer-sponsored benefits are the most effective way to provide workers with access to information and options to protect their financial stability. Working people and their families, particularly those at lower and middle incomes, are perhaps the most vulnerable in today's economy yet are often overlooked by many providers of financial products and services. For many of these workers and families, employer-sponsored benefits are the primary defense against the potentially catastrophic financial impact of death, illness, or injury.
We have established a corporate culture consistent with the social value of our products and services. Because we see important links between the obligations we have to all of our stakeholders, we place a strong emphasis on operating with integrity and contributing to positive change in our communities. Accordingly, we are committed not only to meeting the needs of our customers who depend on us, but also to being accountable for our actions through sound and consistent business practices, a strong internal compliance program, a comprehensive risk management strategy, and an engaged employee workforce.
This discussion and analysis should be read in conjunction with the consolidated financial statements and notes thereto in Part I, Item 1 contained in this Form 10-Q and with the "Cautionary Statement Regarding Forward-Looking Statements" included below the Table of Contents, as well as the discussion, analysis, and consolidated financial statements and notes thereto in Part I, Items 1 and 1A, and Part II, Items 7, 7A, and 8 of our annual report on Form 10-K for the year ended December 31, 2023.
Operating Performance and Capital Management
For the third quarter of 2024, we reported net income of $645.7 million, or $3.46 per diluted common share, compared to net income of $202.0 million, or $1.02 per diluted common share, in the third quarter of 2023. For the first nine months of 2024, we reported net income of $1,430.4 million, or $7.52 per diluted common share, compared to net income of $953.2 million, or $4.81 per diluted common share in the same period of 2023.
Included in our results for the third quarter of 2024 are:
- A net investment loss of $12.9 million before tax and $9.8 million after tax, or $0.05 per diluted common share;
- Amortization of the cost of reinsurance of $10.4 million before tax and $8.2 million after tax, or $0.04 per diluted common share;
- Non-contemporaneous reinsurance of $6.0 million before tax and $4.8 million after tax, or $0.03 per diluted common share;
- A net reserve decrease related to assumption updates of $357.4 million before tax and $282.6 million after tax, or $1.51 per diluted common share; and
- A loss resulting from a legal settlement of $15.3 million before tax and $12.1 million after tax, or $0.06 per diluted common share.
Included in our results for the first nine months of 2024 are:
- A net investment loss of $24.5 million before tax and $18.8 million after tax, or $0.10 per diluted common share;
- Amortization of the cost of reinsurance of $31.1 million before tax and $24.6 million after tax, or $0.13 per diluted common share;
- Non-contemporaneous reinsurance of $20.2 million before tax and $16.0 million after tax, or $0.08 per diluted common share;
- A net reserve decrease related to assumption updates of $357.4 million before tax and $282.6 million after tax, or $1.48 per diluted common share; and
- A loss resulting from a legal settlement of $15.3 million before tax and $12.1 million after tax, or $0.06 per diluted common share.
Included in our results for the third quarter of 2023 are:
- A net investment loss of $31.0 million before tax and $24.4 million after tax, or $0.13 per diluted common share;
- Amortization of the cost of reinsurance of $11.1 million before tax and $8.7 million after tax, or $0.04 per diluted common share;
- Non-contemporaneous reinsurance of $9.2 million before tax and $7.3 million after tax, or $0.04 per diluted common share; and
- A net reserve increase related to assumption updates of $177.2 million before tax and $139.3 million after tax, or $0.71 per diluted common share.
Included in our results for the first nine months of 2023 are:
- A net investment loss of $30.0 million before tax and $23.6 million after tax, or $0.12 per diluted common share;
- Amortization of the cost of reinsurance $33.1 million before tax and $26.1 million after tax, or $0.13 per diluted common share;
- Non-contemporaneous reinsurance of $26.4 million before tax and $20.9 million after tax, or $0.11 per diluted common share; and
- A net reserve increase related to assumption updates of $177.2 million before tax and $139.3 million after tax, or $0.70 per diluted common share.
Excluding these items, after-tax adjusted operating income for the third quarter of 2024 was $398.0 million, or $2.13 per diluted common share compared to $381.7 million, or $1.94 per diluted common share, for the same period of 2023. After-tax adjusted operating income was $1,219.3 million, or $6.41 per diluted common share, in the first nine months of 2024, compared to $1,163.1 million, or $5.87 per diluted common share, in the first nine months of 2023. See "Reconciliation of Non-GAAP and Other Financial Measures" contained herein in this Item 2 for a reconciliation of these items.
Our Unum US segment reported income before income tax and net investment gains and losses of $506.9 million and $1,249.6 million in the third quarter and first nine months of 2024, respectively, compared to $486.6 million and $1,142.2 million in the same periods of 2023, which includes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. Excluding these items, our Unum US segment reported adjusted operating income of $363.3 million and $1,106.0 million in the third quarter and first nine months of 2024, respectively, compared to $357.8 million and $1,013.4 million in the same periods of 2023, due to favorable benefits experience primarily in our group life product line as well as an increase in premium income, partially offset by higher commissions. Also impacting the comparison for the third quarter of 2024 compared to the same period of 2023 was unfavorable benefits experience in our group disability product line. The benefit ratio, excluding the reserve assumption updates, for our Unum US segment was 58.5 percent and 57.8 percent in the third quarter and first nine months of 2024, respectively, compared to 59.1 percent and 59.9 percent in third quarter and first nine months of 2023, respectively. Unum US sales decreased 9.7 percent and 2.7 percent in the third quarter and first nine months of 2024, respectively, compared to the same periods of 2023.
Our Unum International segment reported income before income tax and net investment gains and losses of $32.8 million and $112.7 million in the third quarter and first nine months of 2024, respectively, compared to $18.9 million and $100.8 million in the same periods of 2023, which includes the reserve assumption updates during the third quarters of 2024 and 2023. Excluding these items, our Unum International segment reported adjusted operating income of $40.3 million and $120.2 million in the third quarter and first nine months of 2024, compared to $36.8 million and $118.7 million in the same periods of 2023. Our Unum UK line of business reported adjusted operating income, which excludes the reserve assumption updates, of £29.5 million in the third quarter of 2024 compared to £28.4 million in the same period of 2023, primarily due to higher premium income as well as higher net investment income, partially offset by unfavorable benefits experience. Our Unum UK line of business reported adjusted operating income of £90.2 million in the first nine months of 2024, compared to £93.7 million in the same period of 2023, primarily due to lower net investment income and higher operating expenses, partially offset by higher premium income. The benefit ratio for our Unum UK line of business, excluding the reserve assumption updates, was 69.5 percent and 69.0 percent in the third quarter and first nine months of 2024, respectively, compared to 67.4 percent and 69.4 percent in the same periods of 2023. Unum International sales, as measured in U.S. dollars, increased 26.5 percent and 8.4 percent in the third quarter and first nine months of 2024, respectively, compared to the same periods of 2023. Unum UK sales, as measured in local currency, increased 26.9 percent and 6.9 percent in the third quarter and first nine months of 2024, respectively, compared to the same periods of 2023.
Our Colonial Life segment reported income before income tax and net investment gains and losses of $159.4 million and $390.0 million in the third quarter and first nine months of 2024, respectively, compared to $183.6 million and $393.0 million in the same periods of 2023, which includes the reserve assumption updates during the third quarters of 2024 and 2023. Excluding these items, our Colonial Life segment reported adjusted operating income of $113.4 million and $344.0 million in the third quarter and first nine months of 2024, compared to $102.9 million and $312.3 million in the same periods of 2023, primarily due to higher premium income and favorable benefits experience, partially offset by higher commissions. Also impacting the comparison for the first nine months of 2024 is higher amortization of deferred acquisition costs. The benefit ratio, excluding the reserve assumption updates, for Colonial Life was 47.6 percent and 48.0 percent in the third quarter and first nine months of 2024, respectively, compared to 49.1 percent and 50.2 percent in the same periods of 2023. Colonial Life sales decreased 0.3 percent and 0.9 percent in the third quarter and first nine months of 2024, respectively, compared to the same periods of 2023.
Our Closed Block segment reported income before income tax and net investment gains and losses of $193.1 million and $234.1 million in the third quarter and first nine months of 2024, respectively, compared to a loss before income tax and net investment gains and losses of $354.9 million and $284.7 million in the same periods of 2023, all of which include the amortization of the cost of reinsurance and the impact of non-contemporaneous reinsurance related to the Closed Block individual disability reinsurance transaction, as well as the reserve assumption updates during the third quarters of 2024 and 2023. Excluding these items, our Closed Block segment reported adjusted operating income of $34.2 million in the third quarter of 2024, consistent with the same period of 2023, due primarily to an increase in net investment income, offset by lower premium income. Our Closed Block segment reported adjusting operating income of $110.1 million in the first nine months of 2024, compared to $143.6 million in the same period of 2023, due primarily to higher benefits in the long-term care product line and lower premium income, partially offset by an increase in net investment income. The net premium ratio for long-term care increased to 94.5 percent at September 30, 2024 from 93.4 percent at September 30, 2023.
A rising interest rate environment could positively impact our yields on new investments, but could also increase unrealized losses in our current holdings. Alternatively, a declining interest rate environment could negatively impact our yields on new investments, but could also reduce unrealized losses in our current holdings. As of September 30, 2024, we do not hold any securities with a decline in fair value below amortized cost which we intend to sell nor any securities for which it is more likely than not that we will be required to sell before recovery in amortized cost. The net unrealized loss on our fixed maturity securities was $1.0 billion at September 30, 2024, compared to $1.6 billion at December 31, 2023, with the decrease due primarily to a decrease in U.S. Treasury rates. The earned book yield on our investment portfolio was 4.41 percent for the first nine months of 2024 compared to a yield of 4.45 percent for full year 2023.
Additionally, a rising interest rate environment could result in reserve decreases while a declining interest rate environment could result in reserve increases, specific to our liability for future policy benefits, as the reserve discount rate assumptions used in the calculation of our liability are updated at each reporting date using a yield that is reflective of an upper-medium grade fixed income instrument, which is generally equivalent to a single-A interest rate matched to the duration of certain of our insurance liabilities. The discount rate assumptions on the liability for future policy benefits, net of reinsurance, as of September 30, 2024, were generally consistent with those as of December 31, 2023.
We believe our capital and financial positions are strong. At September 30, 2024, the risk-based capital (RBC) ratio for our traditional U.S. insurance subsidiaries, calculated on a weighted average basis using the NAIC Company Action Level formula, was approximately 470 percent, which is above our long-term expectation. We repurchased 9.7 million shares and 3.9 million shares of Unum Group common stock under our share repurchase program, during the first nine months of 2024 and 2023, respectively, at a cost of $504.8 million and $175.4 million, respectively, including commissions and excise tax. Our weighted average common shares outstanding, assuming dilution, equaled 186.9 million and 197.1 million for the third quarters of 2024 and 2023, respectively, and 190.2 million and 198.3 million for the first nine months of 2024 and 2023, respectively. As of September 30, 2024, Unum Group and our intermediate holding companies had available holding company liquidity of
$1,393.0 million that was held primarily in bank deposits, commercial paper, money market funds, corporate bonds, municipal bonds and asset backed securities. See Note 12 of the "Notes to Consolidated Financial Statements" contained herein in Item 1.
2024 and 2023 Reserve Assumption Updates
During the third quarters of 2024 and 2023, we completed our annual cash flow assumption review which resulted in the following impacts to net income as a result of updating certain assumptions related to the liability for future policy benefits:
(in millions of dollars)
| Unum US | Three and Nine Months Ended September 30 2024 | 2023 |
|---|---|---|
| Group Disability | $90.0 | $121.0 |
| Group Life and Accidental Death and Dismemberment | 13.0 | — |
| Voluntary Benefits | (12.2) | 10.4 |
| Individual Disability | 52.8 | (2.6) |
| Total Unum US | 143.6 | 128.8 |
| Unum International | (7.5) | (17.9) |
| Colonial Life | 46.0 | 80.7 |
| Closed Block | ||
| Long-term Care | 174.1 | (368.1) |
| Closed Block - All Other | 1.2 | (0.7) |
| Total Closed Block | 175.3 | (368.8) |
| Cash Flow Assumption Update Impacts to Income Before Income Tax | $357.4 | $(177.2) |
| Cash Flow Assumption Update Impacts to Net Income | $282.6 | $(139.3) |
2024 Significant Cash Flow Assumption Updates:
The cash flow assumption updates in our Unum US group long-term disability product line reduced our liability for future policy benefits by $90.0 million, due primarily to claim resolution assumptions driven by favorable claim recovery trends.
The cash flow assumption updates in our Unum US individual disability product line reduced our liability for future policy benefits by $52.8 million, due primarily to favorable claim incidence trends.
The cash flow assumption updates in our Colonial Life segment reduced our liability for future policy benefits by $46.0 million, due primarily to improved claim cost assumptions.
The cash flow assumption updates in our Closed Block segment were primarily driven by the long-term care product line which reduced our liability for future policy benefits by $174.1 million, due primarily to an increase to expected premium rate increase approvals within our existing premium rate increase program, partially offset by lower than expected persistency on group policies.
2023 Significant Cash Flow Assumption Updates:
The cash flow assumption updates in our Unum US group long-term disability product line reduced our liability for future policy benefits by $121.0 million, due primarily to sustained improvement in claim recovery trends.
The cash flow assumption updates in our Colonial Life segment reduced our liability for future policy benefits by $80.7 million, due primarily to improvement in certain of our claim cost assumptions and increased policyholder lapse rates.
The cash flow assumption updates in our Closed Block segment were primarily driven by the long-term care product line which increased our liability for future policy benefits by $368.1 million, due primarily to lower expectations for active policy lapse and mortality assumptions, partially offset by an increase to expected premium rate increase approvals within our existing premium rate increase program.
Loss on Legal Settlement
During the third quarter of 2024, we incurred a loss of $15.3 million before tax, or $12.1 million after tax, within our Corporate segment for the settlement of an employment-related matter. $4.9 million of the loss is recorded within compensation expense and $10.4 million of the loss is recorded within other expenses in the consolidated statements of income.
Inflation Reduction Act
In August 2022, the Inflation Reduction Act (IRA) was signed into law in the U.S. and includes certain corporate tax provisions effective January 1, 2023. The IRA imposes a new 15 percent corporate alternative minimum tax (CAMT) on adjusted financial statement income (AFSI) on corporations that have average AFSI over $1.0 billion in any prior three-year period. Our company is an applicable corporation, but we have not recorded any CAMT for the third quarter or first nine months of 2024 and 2023. We do not expect that any CAMT incurred would impact earnings since it would be offset with a credit toward regular income tax in subsequent years. The IRA also imposes a one percent excise tax on the fair market value of corporate stock repurchases after December 31, 2022. This excise tax is recorded as part of the cost basis of treasury stock and is assessed on the fair market value of stock repurchases, reduced by the fair value of any shares issued during the period. We have recorded $2.0 million and $0.7 million of excise tax in stockholders' equity, as part of the cost basis of treasury stock, for the third quarter of 2024 and 2023, respectively, and $4.8 million and $1.2 million for the first nine months of 2024 and 2023, respectively.
U.K. Tax Law Change
In June 2021, the Finance Act 2021 was enacted, resulting in a U.K. tax rate increase from 19 percent to 25 percent, effective April 1, 2023.
Global Minimum Tax
The Organization for Economic Co-operation and Development (OECD) has established model rules to ensure a minimum level of tax of 15 percent (Pillar Two) for multinational companies. Several jurisdictions, including the United Kingdom and Ireland, have adopted Pillar Two beginning on or after December 31, 2023. We have not recorded Pillar Two taxes as of September 30, 2024, and we do not expect material impacts in 2024. We will continue to monitor legislative developments and refine our estimates as necessary.
Consolidated Company Outlook
We believe our strategy of providing financial protection products at the workplace puts us in a position of strength. We continue to fulfill our corporate purpose of helping the working world thrive throughout life’s moments by providing excellent service to people at their time of need. Our strategy remains centered on growing our core businesses, through investing and transforming our operations and technology to anticipate and respond to the changing needs of our customers, expanding into new adjacent markets through meaningful partnerships and effective deployment of our capital across our portfolio.
In 2023, we experienced increased earnings driven by the underlying strength of our business and expect positive operating trends in our core businesses to continue in 2024. The products and services we provide deliver significant value to employers, employees and their families, and we believe this will help drive sales and premium growth in 2024.
A rising interest rate environment could continue to positively impact our yields on new investments, but could also continue to create unrealized losses in our current holdings. A declining interest rate environment could negatively impact our yields on new investments but could also reduce unrealized losses in our current holdings. We also may continue to experience further volatility in miscellaneous investment income primarily related to changes in partnership net asset values as well as bond calls.
As part of our discipline in pricing and reserving, we continuously monitor emerging claim trends and interest rates. We will continue to take appropriate pricing actions on new business and renewals that are reflective of the current environment and may continue to utilize derivative financial instruments to manage interest rate risk.
Our business is well-diversified by geography within our markets, industry exposures and case size, and we continue to analyze and employ strategies that we believe will help us navigate the current environment. These strategies allow us to maintain financial flexibility to support the needs of our businesses, while also returning capital to our shareholders. We have strong core businesses that have a track record of generating significant free cash flow, and we will continue to invest in our operations and expand into adjacent markets where we can best leverage our expertise and capabilities to capture market growth opportunities as those opportunities emerge. We believe that consistent operating results, combined with the implementation of strategic initiatives and the effective deployment of capital, will allow us to meet our financial objectives.
Further discussion is included in the "Notes to Consolidated Financial Statements" contained herein in Item 1 and in "Reconciliation of Non-GAAP and Other Financial Measures," "Consolidated Operating Results," "Segment Results," "Investments," and "Liquidity and Capital Resources" contained herein in this Item 2.
Reconciliation of Non-GAAP and Other Financial Measures
We analyze our performance using non-GAAP financial measures. A non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP). The non-GAAP financial measure of "after-tax adjusted operating income" differs from net income as presented in our consolidated operating results and income statements prepared in accordance with GAAP due to the exclusion of investment gains or losses, the amortization of the cost of reinsurance, the impact of non-contemporaneous reinsurance, and reserve assumption updates as well as certain other items as specified in the reconciliations below. Investment gains or losses primarily include realized investment gains or losses, expected investment credit losses, and gains or losses on derivatives. We believe after-tax adjusted operating income is a better performance measure and better indicator of the profitability and underlying trends in our business.
Investment gains or losses depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments. Our investment focus is on investment income to support our insurance liabilities as opposed to the generation of investment gains or losses. Although we may experience investment gains or losses which will affect future earnings levels, a long-term focus is necessary to maintain profitability over the life of the business since our underlying business is long-term in nature, and we need to earn the interest rates assumed in calculating our liabilities.
Cash flow assumptions used to calculate our liability for future policy benefits are reviewed at least annually and updated, as needed, with the resulting impact reflected in net income. While the effects of these assumption updates are recorded in the reporting period in which the review is completed, these updates reflect experience emergence and changes to expectations spanning multiple periods. We believe that by excluding the impact of reserve assumption updates we are providing a more comparable and consistent view of our quarterly results.
We exited a substantial portion of our Closed Block individual disability product line through the two phases of the reinsurance transaction that were executed in December 2020 and March 2021. As a result, we exclude the amortization of the cost of reinsurance that we recognized upon the exit of the business related to the policies on claim status as well as the impact of non-contemporaneous reinsurance that resulted from the adoption of ASU 2018-12. Due to the execution of the second phase of the reinsurance transaction occurring after January 1, 2021, the transition date of ASU 2018-12, in accordance with the provisions of the ASU related to non-contemporaneous reinsurance, we were required to establish the ceded reserves using an upper-medium grade fixed-income instrument as of the reinsurance transaction date in March 2021 which resulted in higher ceded reserves compared to that which was reported historically. However, the direct reserves for the block reinsured in the second phase were calculated using the original discount rate utilized as of the transition date. Both the direct and ceded reserves are then remeasured at each reporting period using a current discount rate reflective of an upper-medium grade fixed-income instrument, with the changes recognized in OCI. While the total equity impact is neutral, the different original discount rates utilized for direct and ceded reserves result in disproportionate earnings impacts. The impact of non-contemporaneous reinsurance will fluctuate depending on the magnitude of reserve changes during the period. We believe that the exclusion of these items provides a better view of our results from our ongoing businesses.
We may at other times exclude certain other items from our discussion of financial ratios and metrics in order to enhance the understanding and comparability of our operational performance and the underlying fundamentals, but this exclusion is not an indication that similar items may not recur and does not replace net income or net loss as a measure of our overall profitability.
See "Executive Summary" contained herein in Item 2 and Notes 7 and 14 of the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further discussion regarding the items specified in the reconciliations below.
A reconciliation of GAAP financial measures to our non-GAAP financial measures is as follows:
(in millions)
(in millions)
| Three Months Ended September 30 2024 | per share * | 2023 | per share * | |
|---|---|---|---|---|
| Net Income | $645.7 | $3.46 | $202.0 | $1.02 |
| Excluding: | ||||
| Net Investment Loss (net of tax benefit of $3.1; $6.6) | (9.8) | (0.05) | (24.4) | (0.13) |
| Amortization of the Cost of Reinsurance (net of tax benefit of $2.2; $2.4) | (8.2) | (0.04) | (8.7) | (0.04) |
| Non-Contemporaneous Reinsurance (net of tax benefit of $1.2; $1.9) | (4.8) | (0.03) | (7.3) | (0.04) |
| Reserve Assumption Updates (net of tax expense (benefit) of $74.8; $(37.9)) | 282.6 | 1.51 | (139.3) | (0.71) |
| Loss on Legal Settlement (net of tax benefit of $3.2; $—) | (12.1) | (0.06) | — | — |
| After-tax Adjusted Operating Income | $398.0 | $2.13 | $381.7 | $1.94 |
| *Assuming Dilution |
(in millions)
(in millions)
| Nine Months Ended September 30 2024 | per share * | 2023 | per share * | |
|---|---|---|---|---|
| Net Income | $1,430.4 | $7.52 | $953.2 | $4.81 |
| Excluding: | ||||
| Net Investment Loss (net of tax benefit of $5.7; $6.4) | (18.8) | (0.10) | (23.6) | (0.12) |
| Amortization of the Cost of Reinsurance (net of tax benefit of $6.5; $7.0) | (24.6) | (0.13) | (26.1) | (0.13) |
| Non-Contemporaneous Reinsurance (net of tax benefit of $4.2; $5.5) | (16.0) | (0.08) | (20.9) | (0.11) |
| Reserve Assumption Updates (net of tax expense (benefit) of $74.8; $(37.9)) | 282.6 | 1.48 | (139.3) | (0.70) |
| Loss on Legal Settlement (net of tax benefit of $3.2; $—) | (12.1) | (0.06) | — | — |
| After-tax Adjusted Operating Income | $1,219.3 | $6.41 | $1,163.1 | $5.87 |
| * Assuming Dilution |
We measure and analyze our segment performance on the basis of "adjusted operating revenue" and "adjusted operating income" or "adjusted operating loss", which differ from total revenue and income before income tax as presented in our consolidated statements of income due to the exclusion of investment gains and losses, the amortization of the cost of reinsurance, the impact of non-contemporaneous reinsurance, and reserve assumption updates as well as certain other items as specified in the reconciliations below. These performance measures are in accordance with GAAP guidance for segment reporting, but they should not be viewed as a substitute for total revenue, income before income tax, or net income.
A reconciliation of total revenue to "adjusted operating revenue" and income before income tax to "adjusted operating income" is as follows:
(in millions of dollars)
| Three Months Ended September 30 2024 | 2023 | Nine Months Ended September 30 2024 | 2023 | |
|---|---|---|---|---|
| Total Revenue | $3,217.0 | $3,092.5 | $9,650.7 | $9,240.8 |
| Excluding: | ||||
| Net Investment Loss | (12.9) | (31.0) | (24.5) | (30.0) |
| Adjusted Operating Revenue | $3,229.9 | $3,123.5 | $9,675.2 | $9,270.8 |
| Income Before Income Tax | $814.6 | $261.7 | $1,805.8 | $1,211.4 |
| Excluding: | ||||
| Net Investment Loss | (12.9) | (31.0) | (24.5) | (30.0) |
| Amortization of the Cost of Reinsurance | (10.4) | (11.1) | (31.1) | (33.1) |
| Non-Contemporaneous Reinsurance | (6.0) | (9.2) | (20.2) | (26.4) |
| Reserve Assumption Updates | 357.4 | (177.2) | 357.4 | (177.2) |
| Loss on Legal Settlement | (15.3) | — | (15.3) | — |
| Adjusted Operating Income | $501.8 | $490.2 | $1,539.5 | $1,478.1 |
Critical Accounting Estimates
We prepare our financial statements in accordance with GAAP. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in our financial statements and accompanying notes. Estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed in our financial statements.
The accounting estimates deemed to be most critical to our financial position and results of operations are those related to the liability for future policy benefits, fair value of investments, pension and postretirement benefit plans, income taxes, and contingent liabilities. There have been no significant changes in our critical accounting estimates during the nine months ended September 30, 2024.
For additional information, refer to our significant accounting policies in Note 1 of the "Notes to Consolidated Financial Statements" in Part II, Item 8, and "Critical Accounting Estimates" in Part II, Item 7 of our annual report on Form 10-K for the year ended December 31, 2023.
Accounting Developments
For information on new accounting standards and the impact, if any, on our financial position or results of operations, see Note 2 of the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further information.
Consolidated Operating Results
(in millions of dollars)
| Revenue | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Premium Income | $2,628.8 | 4.1% | $2,525.9 | $7,866.3 | 5.0% | $7,494.3 |
| Net Investment Income | 527.8 | 0.3 | 526.0 | 1,586.4 | 1.3 | 1,565.9 |
| Net Investment Loss | (12.9) | (58.4) | (31.0) | (24.5) | (18.3) | (30.0) |
| Other Income | 73.3 | 2.4 | 71.6 | 222.5 | 5.7 | 210.6 |
| Total Revenue | 3,217.0 | 4.0 | 3,092.5 | 9,650.7 | 4.4 | 9,240.8 |
| Benefits and Expenses | ||||||
| Policy Benefits | 1,864.6 | 4.8 | 1,778.6 | 5,624.2 | 2.3 | 5,498.6 |
| Policy Benefits - Remeasurement Loss (Gain) | (402.7) | N.M. | 168.4 | (567.5) | N.M. | (61.6) |
| Commissions | 315.1 | 8.8 | 289.7 | 947.8 | 9.0 | 869.7 |
| Interest and Debt Expense | 49.2 | 1.2 | 48.6 | 148.6 | 2.1 | 145.6 |
| Deferral of Acquisition Costs | (163.3) | 6.5 | (153.3) | (495.3) | 5.9 | (467.5) |
| Amortization of Deferred Acquisition Costs | 133.8 | 3.6 | 129.1 | 387.9 | 8.1 | 358.7 |
| Compensation Expense | 294.2 | (1.2) | 297.9 | 895.9 | 3.3 | 867.3 |
| Other Expenses | 311.5 | 14.6 | 271.8 | 903.3 | 10.3 | 818.6 |
| Total Benefits and Expenses | 2,402.4 | (15.1) | 2,830.8 | 7,844.9 | (2.3) | 8,029.4 |
| Income Before Income Tax | 814.6 | N.M. | 261.7 | 1,805.8 | 49.1 | 1,211.4 |
| Income Tax Expense | 168.9 | 182.9 | 59.7 | 375.4 | 45.4 | 258.2 |
| Net Income | $645.7 | N.M. | $202.0 | $1,430.4 | 50.1 | $953.2 |
| N.M. = not a meaningful percentage |
Fluctuations in exchange rates, particularly between the British pound sterling and the U.S. dollar for our U.K. operations, have an effect on our consolidated financial results. In periods when the pound weakens relative to the preceding period, translating pounds into dollars decreases current period results relative to the prior period. In periods when the pound strengthens, translating pounds into dollars increases current period results relative to the prior period.
The weighted average pound/dollar exchange rate for our Unum UK line of business was 1.312 and 1.281 for the three months ended September 30, 2024 and 2023, and 1.278 and 1.243 for the nine months ended September 30, 2024 and 2023, respectively. If the 2023 results for our U.K. operations had been translated at the weighted average exchange rates of 2024, our adjusted operating revenue would have been higher by approximately $7 million and $16 million, respectively, in the third quarter and first nine months of 2023 and our adjusted operating income would have been higher by approximately $2 million and $3 million, respectively, for the third quarter and first nine months of 2023. However, it is important to distinguish between translating and converting foreign currency. Except for a limited number of transactions, we do not actually convert pounds into dollars. As a result, we view foreign currency translation as a financial reporting item and not a reflection of operations or profitability in the U.K.
Premium income increased in each of our principal operating segments in the third quarter and first nine months of 2024 compared to the same periods of 2023, primarily due to favorable persistency and higher prior period sales. Premium income continues to decline, as expected, in our Closed Block segment.
Net investment income in the third quarter of 2024 was generally consistent compared to the same period of 2023 due primarily to an increase in the level of invested assets, partially offset by lower yield on invested assets and lower investment income from inflation index-linked bonds held by Unum UK. Net investment income was slightly higher in the first nine months of
2024 compared to the same period of 2023 due primarily to an increase in the level of invested assets and higher miscellaneous investment income, primarily related to larger increases in the net asset value (NAV) on our private equity partnerships, partially offset by lower investment income from inflation index-linked bonds held by Unum UK.
Our investment gains and losses on fixed maturity securities include net losses on sales of $7.4 million and $37.0 million in the third quarter of 2024 and 2023, respectively, and $28.6 million and $47.0 million in the first nine months of 2024 and 2023, respectively. Credit and impairment losses on fixed maturity securities were $1.5 million and $5.6 million during the third quarter and first nine months of 2024, respectively. We did not recognize any credit or impairment losses on fixed maturity securities during the third quarter or first nine months of 2023. Also included in net investment gains and losses were changes in the fair value of an embedded derivative in a modified coinsurance arrangement, which resulted in an investment loss of $0.8 million in the third quarter of 2024 and an investment gain of $9.2 million in the third quarter of 2023, respectively, and investment gains of $6.1 million and $14.7 million in the first nine months of 2024 and 2023, respectively. The changes in the embedded derivative are primarily driven by movements in credit spreads in the overall investment market. See Note 4 in the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further information on investment gains and losses.
Other income is primarily comprised of fee-based service products in the Unum US segment, which include leave management services and administrative services only business, and the underlying results and associated net investment income of certain assumed blocks of reinsured business in the Closed Block segment.
Overall benefits experience was favorable in the third quarter and first nine months of 2024 relative to the same periods of 2023. The consolidated benefit ratio, which includes the remeasurement gain or loss, was 55.6 percent and 64.3 percent in the third quarter and first nine months of 2024, respectively, compared to 77.1 percent and 72.5 percent for the same prior year periods. Excluding the impact of the reserve assumption updates and non-contemporaneous reinsurance, the consolidated benefit ratio was 69.0 percent and 68.6 percent in the third quarter and first nine months of 2024, respectively, compared to 69.7 percent and 69.8 percent for the same prior year periods. The underlying benefits experience for each of our operating business segments is discussed more fully in "Segment Results" as follows.
Commissions and the deferral of acquisition costs were higher during the third quarter and first nine months of 2024 compared to the same periods of 2023 driven primarily by higher prior period sales in our principal operating segments. The increase in the amortization of deferred acquisition costs in the third quarter and first nine months of 2024 compared to the same periods of 2023 is due primarily to growth in the level of the deferred asset in our Unum US supplemental and voluntary and Unum US group disability product lines. Also impacting the increase in the amortization of deferred acquisition costs for the first nine months of 2024 compared to the same period of 2023 is growth in the level of the deferred asset in our Colonial Life Segment.
Other expenses and compensation expense, on a combined basis, increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to a loss from a legal settlement, an increase in operational investments in our business, and growth in our fee-based service products. Also impacting the comparison for the first nine months of 2024 compared to the same period of 2023 were increases in employee-related costs.
Our effective income tax rates for the third quarter and first nine months of 2024 were 20.7 percent and 20.8 percent of income before income tax, respectively, compared to 22.8 percent and 21.3 percent for the same prior year periods. Our effective income tax rates were generally consistent with the U.S. statutory rate of 21 percent in effect for the third quarter of 2024 and for the first nine months of 2023 and 2024. Our effective income tax rate differed from the U.S. statutory rate of 21 percentage for the third quarter of 2023 primarily due to interest on uncertain tax positions.
Consolidated Sales Results
Shown below are sales results for our three principal operating business segments.
(in millions)
| Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 | |
|---|---|---|---|---|---|---|
| Unum US | $154.3 | (9.7)% | $170.9 | $741.6 | (2.7)% | $762.1 |
| Unum International | $38.2 | 26.5% | $30.2 | $148.1 | 8.4% | $136.6 |
| Colonial Life | $120.9 | (0.3)% | $121.3 | $346.8 | (0.9)% | $350.1 |
Sales shown in the preceding chart generally represent the annualized premium income on new sales which we expect to receive and report as premium income during the next 12 months following or beginning in the initial quarter in which the sale is reported, depending on the effective date of the new sale. Sales do not correspond to premium income reported as revenue in accordance with GAAP. This is because new annualized sales premiums reflect current sales performance and what we expect to recognize as premium income over a 12 month period, while premium income reported in our financial statements is reported on an "as earned" basis rather than an annualized basis and also includes renewals and persistency of in-force policies written in prior years as well as current new sales.
Sales, persistency of the existing block of business, employment and salary growth, and the effectiveness of a renewal program are indicators of growth in premium income. Trends in new sales, as well as existing market share, also indicate the potential for growth in our respective markets and the level of market acceptance of price levels and new product offerings. Sales results may fluctuate significantly due to case size and timing of sales submissions.
See "Segment Results" as follows for a discussion of sales by segment.
Segment Results
Our reporting segments are comprised of the following: Unum US, Unum International, Colonial Life, Closed Block, and Corporate.
In describing our results, we may at times note certain items and exclude the impact on financial ratios and metrics to enhance the understanding and comparability of our operational performance and the underlying fundamentals, but this exclusion is not an indication that similar items may not recur. We also measure and analyze our segment performance on the basis of "adjusted operating revenue" and "adjusted operating income" or "adjusted operating loss", which differ from total revenue and income before income tax as presented in our consolidated statements of income due to the exclusion of investment gains and losses and certain other items. These performance measures are in accordance with GAAP guidance for segment reporting, but they should not be viewed as a substitute for total revenue, income before income tax, or net income. See "Reconciliation of Non-GAAP Financial Measures" contained herein in this Item 2.
Unum US Segment
The Unum US segment is comprised of the group disability, group life and accidental death and dismemberment, and supplemental and voluntary lines of business. The group disability line of business includes long-term and short-term disability, medical stop-loss, and fee-based service products. The supplemental and voluntary line of business includes voluntary benefits, individual disability, and dental and vision products. These products, excluding medical stop loss which is no longer actively marketed as of the third quarter of 2024, are marketed through our field sales personnel who work in conjunction with independent brokers and consultants.
Unum US Operating Results
Shown below are financial results for the Unum US segment. In the sections following, financial results and key ratios are also presented for the major lines of business within the segment.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Premium Income | $1,723.5 | 4.0% | $1,657.7 | $5,161.8 | 5.2% | $4,908.7 |
| Net Investment Income | 161.0 | (3.1) | 166.2 | 476.1 | (1.1) | 481.5 |
| Other Income | 60.1 | 3.6 | 58.0 | 178.9 | 7.7 | 166.1 |
| Total | 1,944.6 | 3.3 | 1,881.9 | 5,816.8 | 4.7 | 5,556.3 |
| Benefits and Expenses | ||||||
| Policy Benefits | 1,046.0 | 5.2 | 994.3 | 3,207.2 | 0.4 | 3,195.6 |
| Policy Benefits - Remeasurement Gain | (181.9) | 26.3 | (144.0) | (367.2) | (4.1) | (383.0) |
| Commissions | 182.6 | 11.1 | 164.3 | 551.9 | 11.8 | 493.7 |
| Deferral of Acquisition Costs | (81.6) | 9.5 | (74.5) | (247.4) | 7.3 | (230.6) |
| Amortization of Deferred Acquisition Costs | 75.7 | 8.1 | 70.0 | 216.7 | 8.8 | 199.2 |
| Other Expenses | 396.9 | 3.0 | 385.2 | 1,206.0 | 5.9 | 1,139.2 |
| Total | 1,437.7 | 3.0 | 1,395.3 | 4,567.2 | 3.5 | 4,414.1 |
| Income Before Income Tax and Net Investment Gains and Losses | 506.9 | 4.2 | 486.6 | 1,249.6 | 9.4 | 1,142.2 |
| Reserve Assumption Updates | (143.6) | 11.5 | (128.8) | (143.6) | 11.5 | (128.8) |
| Adjusted Operating Income | $363.3 | 1.5 | $357.8 | $1,106.0 | 9.1 | $1,013.4 |
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratio1 | 58.5% | 59.1% | 57.8% | 59.9% | ||
| Other Expense Ratio2 | 22.3% | 22.5% | 22.6% | 22.5% | ||
| Income Ratio | 29.4% | 29.4% | 24.2% | 23.3% | ||
| Adjusted Operating Income Ratio | 21.1% | 21.6% | 21.4% | 20.6% | ||
| 1Excludes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. | ||||||
| 2Ratio of Other Expenses to Premium Income plus Unum US Group Disability Other Income, which is primarily related to fee-based services. |
99
Unum US Group Disability Operating Results
Shown below are financial results and key performance indicators for Unum US group disability.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Long-term Disability | $522.1 | 0.7% | $518.5 | $1,560.3 | 1.4% | $1,539.3 |
| Group Short-term Disability | 271.3 | 5.8 | 256.5 | 810.7 | 7.7 | 753.0 |
| Total Premium Income | 793.4 | 2.4 | 775.0 | 2,371.0 | 3.4 | 2,292.3 |
| Net Investment Income | 78.7 | (6.5) | 84.2 | 234.8 | (4.7) | 246.4 |
| Other Income | 58.6 | 13.3 | 51.7 | 174.8 | 10.6 | 158.1 |
| Total | 930.7 | 2.2 | 910.9 | 2,780.6 | 3.1 | 2,696.8 |
| Benefits and Expenses | ||||||
| Policy Benefits | 500.4 | 6.1 | 471.5 | 1,541.7 | 0.1 | 1,539.9 |
| Policy Benefits - Remeasurement Gain | (121.4) | (17.2) | (146.7) | (242.4) | (21.7) | (309.5) |
| Commissions | 60.0 | 4.9 | 57.2 | 184.1 | 6.7 | 172.6 |
| Deferral of Acquisition Costs | (15.4) | 7.7 | (14.3) | (48.1) | 7.6 | (44.7) |
| Amortization of Deferred Acquisition Costs | 18.2 | 12.3 | 16.2 | 46.8 | 11.2 | 42.1 |
| Other Expenses | 242.2 | 2.7 | 235.9 | 733.8 | 4.9 | 699.8 |
| Total | 684.0 | 10.4 | 619.8 | 2,215.9 | 5.5 | 2,100.2 |
| Income Before Income Tax and Net Investment Gains and Losses | 246.7 | (15.3) | 291.1 | 564.7 | (5.3) | 596.6 |
| Reserve Assumption Updates | (90.0) | (25.6) | (121.0) | (90.0) | (25.6) | (121.0) |
| Adjusted Operating Income | $156.7 | (7.9) | $170.1 | $474.7 | (0.2) | $475.6 |
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratio1 | 59.1% | 57.5% | 58.6% | 59.0% | ||
| Other Expense Ratio2 | 28.4% | 28.5% | 28.8% | 28.6% | ||
| Income Ratio | 31.1% | 37.6% | 23.8% | 26.0% | ||
| Adjusted Operating Income Ratio | 19.8% | 21.9% | 20.0% | 20.7% | ||
| Persistency: | ||||||
| Group Long-term Disability | 93.5% | 90.8% | ||||
| Group Short-term Disability | 91.9% | 89.1% | ||||
| 1Excludes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. | ||||||
| 2Ratio of Other Expenses to Premium Income plus Other Income, which is primarily related to fee-based services. |
Premium income was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 driven primarily by favorable persistency and prior period sales. Net investment income was lower in the third quarter and first nine months of 2024 relative to the same periods of 2023 due to a decrease in the level of invested assets, partially offset by an increase in the yield on invested assets. Other income increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due to growth in our fee-based service products.
The benefit ratio, excluding the impacts of the reserve assumption updates, was unfavorable in the third quarter of 2024 compared to the same period of 2023 due to higher incidence in our long-term disability and short-term disability product lines and higher average claim size in the long-term disability product line, partially offset by favorable recoveries in the long-term disability product line. The benefit ratio, excluding the impacts of the reserve assumption updates, was favorable during the first nine months of 2024 compared to the same period of 2023 due to favorable recoveries, partially offset by higher average claim size, in our long-term disability product line. Also impacting the third quarter and the first nine months of 2024 compared to the same periods of 2023 was favorable stop loss experience.
Commissions and the deferral of acquisition costs were higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to higher prior period sales. The amortization of deferred acquisition costs was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 primarily due to growth in the level of the deferred asset. The other expense ratio, which includes other income that is primarily related to fee-based service products, was generally consistent in the third quarter and the first nine months of 2024 related to the same periods of 2023.
Unum US Group Life and Accidental Death and Dismemberment Operating Results
Shown below are financial results and key performance indicators for Unum US group life and accidental death and dismemberment.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Life | $447.8 | 5.9% | $423.0 | $1,337.9 | 6.7% | $1,254.3 |
| Accidental Death & Dismemberment | 47.1 | 6.8 | 44.1 | 139.3 | 6.2 | 131.2 |
| Total Premium Income | 494.9 | 6.0 | 467.1 | 1,477.2 | 6.6 | 1,385.5 |
| Net Investment Income | 22.1 | (6.8) | 23.7 | 66.6 | (2.3) | 68.2 |
| Other Income | 0.3 | 50.0 | 0.2 | 1.4 | 100.0 | 0.7 |
| Total | 517.3 | 5.4 | 491.0 | 1,545.2 | 6.2 | 1,454.4 |
| Benefits and Expenses | ||||||
| Policy Benefits | 333.7 | (3.4) | 345.5 | 1,027.9 | (2.1) | 1,050.1 |
| Policy Benefits - Remeasurement Gain | (24.9) | N.M. | (2.9) | (62.8) | 121.9 | (28.3) |
| Commissions | 42.1 | 8.5 | 38.8 | 126.5 | 8.3 | 116.8 |
| Deferral of Acquisition Costs | (10.0) | 11.1 | (9.0) | (31.0) | 7.3 | (28.9) |
| Amortization of Deferred Acquisition Costs | 9.6 | (5.9) | 10.2 | 26.7 | (9.5) | 29.5 |
| Other Expenses | 59.8 | 6.0 | 56.4 | 183.0 | 6.7 | 171.5 |
| Total | 410.3 | (6.5) | 439.0 | 1,270.3 | (3.1) | 1,310.7 |
| Income Before Income Tax and Net Investment Gains and Losses | 107.0 | 105.8 | 52.0 | 274.9 | 91.3 | 143.7 |
| Reserve Assumption Update | (13.0) | (100.0) | — | (13.0) | (100.0) | — |
| Adjusted Operating Income | $94.0 | 80.8 | $52.0 | $261.9 | 82.3 | $143.7 |
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratio1 | 65.0% | 73.3% | 66.2% | 73.7% | ||
| Other Expense Ratio | 12.1% | 12.1% | 12.4% | 12.4% | ||
| Income Ratio | 21.6% | 18.6% | ||||
| Adjusted Operating Income Ratio | 19.0% | 11.1% | 17.7% | 10.4% | ||
| Persistency: | ||||||
| Group Life | 92.0% | 89.3% | ||||
| Accidental Death & Dismemberment | 91.2% | 88.2% | ||||
| 1Excludes the reserve assumption update that occurred during the third quarter of 2024. | ||||||
| N.M. = not a meaningful percentage |
Premium income increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due to favorable persistency and prior period sales. Net investment income was lower in the third quarter and first nine months of 2024 relative to the same periods of 2023 due to a decrease in the level of invested assets, partially offset by an increase in the yield on invested assets.
The benefit ratio, excluding the impacts of the reserve assumption update, was favorable in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to favorable incidence in our group life product line.
Commissions and the deferral of acquisition costs were higher in the third quarter and first nine months of 2024 compared to the same period of 2023 due to higher prior period sales. The amortization of deferred acquisition costs was lower in the third quarter and the first nine months of 2024 compared to the same periods of 2023 due primarily to favorable overall persistency. The other expense ratio was consistent in the third quarter and first nine months of 2024 compared to the same periods of 2023.
Unum US Supplemental and Voluntary Operating Results
Shown below are financial results and key performance indicators for Unum US supplemental and voluntary product lines.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Voluntary Benefits | $219.3 | 4.7% | $209.5 | $665.1 | 4.3% | $637.4 |
| Individual Disability | 140.4 | 2.7 | 136.7 | 424.6 | 9.8 | 386.7 |
| Dental and Vision | 75.5 | 8.8 | 69.4 | 223.9 | 8.3 | 206.8 |
| Total Premium Income | 435.2 | 4.7 | 415.6 | 1,313.6 | 6.7 | 1,230.9 |
| Net Investment Income | 60.2 | 3.3 | 58.3 | 174.7 | 4.7 | 166.9 |
| Other Income | 1.2 | (80.3) | 6.1 | 2.7 | (63.0) | 7.3 |
| Total | 496.6 | 3.5 | 480.0 | 1,491.0 | 6.1 | 1,405.1 |
| Benefits and Expenses | ||||||
| Policy Benefits | 211.9 | 19.5 | 177.3 | 637.6 | 5.3 | 605.6 |
| Policy Benefits - Remeasurement Loss (Gain) | (35.6) | N.M. | 5.6 | (62.0) | 37.2 | (45.2) |
| Commissions | 80.5 | 17.9 | 68.3 | 241.3 | 18.1 | 204.3 |
| Deferral of Acquisition Costs | (56.2) | 9.8 | (51.2) | (168.3) | 7.2 | (157.0) |
| Amortization of Deferred Acquisition Costs | 47.9 | 9.9 | 43.6 | 143.2 | 12.2 | 127.6 |
| Other Expenses | 94.9 | 2.2 | 92.9 | 289.2 | 8.0 | 267.9 |
| Total | 343.4 | 2.1 | 336.5 | 1,081.0 | 7.8 | 1,003.2 |
| Income Before Income Tax and Net Realized Investment Gains and Losses | 153.2 | 6.8 | 143.5 | 410.0 | 2.0 | 401.9 |
| Reserve Assumption Updates - Voluntary Benefits | 12.2 | N.M. | (10.4) | 12.2 | N.M. | (10.4) |
| Reserve Assumption Updates - Individual Disability | (52.8) | N.M. | 2.6 | (52.8) | N.M. | 2.6 |
| Adjusted Operating Income | $112.6 | (17.0) | $135.7 | $369.4 | (6.3) | $394.1 |
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratios: | ||||||
| Voluntary Benefits1 | 45.8% | 39.1% | 41.6% | 38.1% | ||
| Individual Disability1 | 42.8% | 45.4% | 41.0% | 44.3% | ||
| Dental and Vision | 74.6% | 67.4% | 74.1% | 74.6% | ||
| Other Expense Ratio | 21.8% | 22.4% | 22.0% | 21.8% | ||
| Income Ratio | 35.2% | 34.5% | 31.2% | 32.7% | ||
| Adjusted Operating Income Ratio | 25.9% | 32.7% | 28.1% | 32.0% | ||
| Persistency: | ||||||
| Voluntary Benefits | 76.4% | 75.5% | ||||
| Individual Disability | 89.0% | 89.3% | ||||
| Dental and Vision | 81.4% | 76.2% | ||||
| 1Excludes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. | ||||||
| N.M. = not a meaningful percentage |
Premium income was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023, due to favorable persistency in the voluntary benefits and dental and vision product lines and higher prior period sales in the voluntary benefits and individual disability product lines. Also impacting the comparison for the first nine months of 2024 compared to the same period of 2023 was the continued impacts from the partial recapture of a previously ceded block of business in the individual disability product line. Net investment income increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 primarily due to an increase in the yield on invested assets. Other income decreased in the third quarter and first nine months of 2024 compared to the same period of 2023, due primarily to a prior year net gain on the partial recapture of a previously ceded block of business in the individual disability product line.
The benefit ratio, excluding the impacts of the reserve assumption updates, for voluntary benefits was unfavorable in the third quarter of 2024 compared to the same period of 2023 due to unfavorable experience in the critical illness and life product lines. The benefit ratio, excluding the impacts of the reserve assumption updates, for voluntary benefits was unfavorable in the first nine months of 2024 compared to the same period of 2023 due to less favorable experience in the critical illness, hospital indemnity, and accident product lines. The benefit ratio, excluding the impacts of the reserve assumption updates, for the individual disability product line was favorable in the third quarter and the first nine months of 2024 compared to the same periods of 2023 due primarily to favorable recoveries, partially offset by higher claim size. The benefit ratio for the dental and vision product line was unfavorable in the third quarter of 2024 compared to the same period of 2023 due primarily to higher claims incidence and higher average claim size. The benefit ratio for the dental and vision product line was generally consistent in the first nine months of 2024 compared to the same period of 2023.
Commissions and deferral of acquisition costs were higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to higher prior period sales in the voluntary benefits product line. Also impacting the comparison for the first nine months of 2024 compared to 2023 was higher prior period sales in the individual disability product line. The amortization of deferred acquisition costs was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to increased lapses in certain older product offerings in the voluntary benefits product line and growth in the level of the deferred assets in all product lines. The other expense ratio was favorable in the third quarter of 2024 compared to the same period of 2023 due to our focus on expense management and operating efficiencies. The other expense ratio was generally consistent in the first nine months of 2024 compared to the same period of 2023.
Sales
(in millions of dollars)
| Sales by Product Group Disability and Group Life and AD&D | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Long-term Disability | $24.4 | (33.3)% | $36.6 | $143.8 | (7.9)% | $156.1 |
| Group Short-term Disability | 15.9 | (47.9) | 30.5 | 94.1 | (19.6) | 117.1 |
| Group Life and AD&D | 26.5 | 5.2 | 25.2 | 151.2 | (1.1) | 152.9 |
| Subtotal | 66.8 | (27.6) | 92.3 | 389.1 | (8.7) | 426.1 |
| Supplemental and Voluntary | ||||||
| Voluntary Benefits | 45.6 | 16.9 | 39.0 | 233.0 | 9.6 | 212.5 |
| Individual Disability | 29.4 | 14.8 | 25.6 | 76.1 | (6.0) | 81.0 |
| Dental and Vision | 12.5 | (10.7) | 14.0 | 43.4 | 2.1 | 42.5 |
| Subtotal | 87.5 | 11.3 | 78.6 | 352.5 | 4.9 | 336.0 |
| Total Sales | $154.3 | (9.7) | $170.9 | $741.6 | (2.7) | $762.1 |
| Sales by Market Sector | ||||||
| Group Disability and Group Life and AD&D | ||||||
| Core Market (< 2,000 employees) | $52.1 | (20.8)% | $65.8 | $247.1 | (3.1)% | $255.1 |
| Large Case Market | 14.7 | (44.5) | 26.5 | 142.0 | (17.0) | 171.0 |
| Subtotal | 66.8 | (27.6) | 92.3 | 389.1 | (8.7) | 426.1 |
| Supplemental and Voluntary | 87.5 | 11.3 | 78.6 | 352.5 | 4.9 | 336.0 |
| Total Sales | $154.3 | (9.7) | $170.9 | $741.6 | (2.7) | $762.1 |
Group sales decreased during the third quarter of 2024 compared to the same period of 2023 due to lower sales to new and existing customers in both the large case market, which we define as employee groups with greater than 2,000 employees, and the core market. Group sales decreased during the first nine months of 2024 compared to the same period of 2023 due to lower sales to new customers in the large case market and existing customers in both the large case and core markets, partially offset by higher sales to new customers in the core market. The sales mix in the group market sector for the first nine months of 2024 was approximately 64 percent core market and 36 percent large case market.
Voluntary benefits sales increased during the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to higher sales to new customers in the large case market and higher sales to new and existing customers in the core market. Also impacting the comparison of the third quarter of 2024 to the same period of 2023 was higher sales to existing customers in the large case market. Individual disability sales, which are primarily concentrated in the multi-life market, increased in the third quarter of 2024 compared to the same period of 2023 due to higher sales to existing and new customers. Individual disability sales decreased during the first nine months of 2024 compared to the same period of 2023 primarily due to lower sales to new customers, partially offset by higher sales to existing customers. Dental and vision sales decreased during the third quarter of 2024 compared to the same period of 2023 due primarily to lower sales to new customers. Dental and vision sales increased during the first nine months of 2024 compared to the same period of 2023 due primarily to higher sales to new customers.
We remain committed to offering consumers a broad set of financial protection benefit products at the worksite. During 2024, we will continue to invest in a unique customer experience defined by simplicity, empathy, and deep industry expertise through the increased utilization of digital capabilities and technology to enhance enrollment, underwriting, the client administration experience, and claims processing. In addition, we will focus on strategically driven sales by enhancing the connectivity, alignment, and support for brokers and technology partners. With respect to smaller employers, we will continue to provide a comprehensive set of consumer-focused products, enhance our distribution model, and utilize our digital tools to bring industry leading enrollment capabilities and a fully integrated customer experience. Our differentiated offerings and market leading leave management services provide substantial growth opportunities, particularly with larger employers, and stronger persistency in our core products. We believe our active client management, integrated customer experience across our product lines, and strong risk management, will enable us to continue to grow our market over the long-term.
We expect strong adjusted operating income in 2024 with continued premium growth and claim experience in line with 2023. We expect premium growth to be driven by improved persistency in most lines as well as continued strong sales momentum. We expect the group disability market to remain competitive which may impact our pricing and renewal premium levels. We expect favorable group disability claim experience to continue in 2024, driven by strong operational performance. We also expect group life and voluntary benefits claim experience to be mostly stable. We expect a stable operating expense ratio as our investments in our people and capabilities are offset by efficiencies gained from our strategic initiatives.
A rising interest rate environment could continue to positively impact our yields on new investments but could also continue to create further unrealized losses in our current holdings. A declining interest rate environment could negatively impact yields on new investments but could also reduce unrealized losses in our current holdings. Our net investment income may continue to be impacted by volatility in miscellaneous investment income.
As part of our discipline in pricing and reserving, we continuously monitor emerging claim trends and interest rates. We will continue to take appropriate pricing actions on new business and renewals that are reflective of the current environment.
We continuously monitor key indicators to assess our risks and adjust our business plans accordingly.
Unum International Segment
The Unum International segment is comprised of our operations in both the United Kingdom and Poland. Our Unum UK products include insurance for group long-term disability, group life, and supplemental lines of business, which includes dental, critical illness, and individual disability products. Our Unum Poland products include insurance for individual and group life with accident and health riders. Unum International's products are sold primarily through field sales personnel and independent brokers and consultants.
Operating Results
Shown below are financial results and key performance indicators for the Unum International segment.
(in millions of dollars)
| Adjusted Operating Revenue Premium Income Unum UK | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Long-term Disability | $106.6 | 5.4% | $101.1 | $312.4 | 5.0% | $297.5 |
| Group Life | 58.8 | 33.0 | 44.2 | 156.3 | 25.5 | 124.5 |
| Supplemental | 41.4 | 19.7 | 34.6 | 125.1 | 25.2 | 99.9 |
| Unum Poland | 39.8 | 29.6 | 30.7 | 113.3 | 33.0 | 85.2 |
| Total Premium Income | 246.6 | 17.1 | 210.6 | 707.1 | 16.5 | 607.1 |
| Net Investment Income | 30.4 | 11.4 | 27.3 | 94.5 | (9.1) | 104.0 |
| Other Income | 0.4 | (20.0) | 0.5 | 1.2 | 20.0 | 1.0 |
| Total | 277.4 | 16.4 | 238.4 | 802.8 | 12.7 | 712.1 |
| Benefits and Expenses | ||||||
| Policy Benefits | 192.7 | 19.8 | 160.9 | 511.9 | 16.3 | 440.1 |
| Policy Benefits - Remeasurement Gain | (17.4) | N.M. | (2.4) | (24.5) | N.M. | (6.8) |
| Commissions | 21.7 | 18.6 | 18.3 | 61.7 | 14.7 | 53.8 |
| Deferral of Acquisition Costs | (4.6) | 21.1 | (3.8) | (13.2) | 22.2 | (10.8) |
| Amortization of Deferred Acquisition Costs | 2.5 | 4.2 | 2.4 | 7.3 | 19.7 | 6.1 |
| Other Expenses | 49.7 | 12.7 | 44.1 | 146.9 | 14.0 | 128.9 |
| Total | 244.6 | 11.4 | 219.5 | 690.1 | 12.9 | 611.3 |
| Income Before Income Tax and Net Investment Gains and Losses | 32.8 | 73.5 | 18.9 | 112.7 | 11.8 | 100.8 |
| Reserve Assumption Updates | 7.5 | (58.1) | 17.9 | 7.5 | (58.1) | 17.9 |
| Adjusted Operating Income | $40.3 | 9.5 | $36.8 | $120.2 | 1.3 | $118.7 |
| N.M. = not a meaningful percentage |
Foreign Currency Translation
The functional currencies of Unum UK and Unum Poland are the British pound sterling and Polish zloty, respectively. Premium income, net investment income, claims, and expenses are received or paid in the functional currency, and we hold functional currency-denominated assets to support functional currency-denominated policy liabilities. We translate functional currency-denominated financial statement items into dollars for our consolidated financial reporting. We translate income statement items using an average exchange rate for the reporting period, and we translate balance sheet items using the exchange rate at the end of the period. We report unrealized foreign currency translation gains and losses in accumulated other comprehensive income in our consolidated balance sheets.
Fluctuations in exchange rates impact Unum International's reported financial results and our consolidated financial results. In periods when the functional currency strengthens relative to the preceding period, translation increases current period results relative to the prior period. In periods when the functional currency weakens, translation decreases current period results relative to the prior period.
Unum UK Operating Results
Shown below are financial results and key performance indicators for the Unum UK product lines in functional currency.
(in millions of pounds, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Long-term Disability | £82.0 | 2.8% | £79.8 | £244.6 | 2.4% | £238.9 |
| Group Life | 45.1 | 29.2 | 34.9 | 122.2 | 22.2 | 100.0 |
| Supplemental | 31.8 | 15.6 | 27.5 | 97.9 | 21.9 | 80.3 |
| Total Premium Income | 158.9 | 11.7 | 142.2 | 464.7 | 10.9 | 419.2 |
| Net Investment Income | 21.2 | 8.7 | 19.5 | 67.5 | (13.1) | 77.7 |
| Other Income | 0.1 | 100.0 | — | 0.2 | 100.0 | 0.1 |
| Total | 180.2 | 11.4 | 161.7 | 532.4 | 7.1 | 497.0 |
| Benefits and Expenses | ||||||
| Policy Benefits | 130.2 | 14.7 | 113.5 | 346.8 | 10.9 | 312.6 |
| Policy Benefits - Remeasurement Gain | (13.4) | N.M. | (1.4) | (19.7) | N.M. | (5.3) |
| Commissions | 9.9 | 6.5 | 9.3 | 29.0 | 2.5 | 28.3 |
| Deferral of Acquisition Costs | (0.8) | (11.1) | (0.9) | (2.8) | (6.7) | (3.0) |
| Amortization of Deferred Acquisition Costs | 1.2 | (7.7) | 1.3 | 4.0 | 5.3 | 3.8 |
| Other Expenses | 30.0 | 7.9 | 27.8 | 91.3 | 9.7 | 83.2 |
| Total | 157.1 | 5.0 | 149.6 | 448.6 | 6.9 | 419.6 |
| Income Before Income Tax and Net Investment Gains and Losses | 23.1 | 90.9 | 12.1 | 83.8 | 8.3 | 77.4 |
| Reserve Assumption Updates | 6.4 | (60.7) | 16.3 | 6.4 | (60.7) | 16.3 |
| Adjusted Operating Income | £29.5 | 3.9 | £28.4 | £90.2 | (3.7) | £93.7 |
| Weighted Average Pound/Dollar Exchange Rate | 1.312 | 1.281 | 1.278 | 1.243 | ||
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratio1 | 69.5% | 67.4% | 69.0% | 69.4% | ||
| Other Expense Ratio | 18.9% | 19.5% | 19.6% | 19.8% | ||
| Income Ratio | 14.5% | 8.5% | 18.0% | 18.5% | ||
| Adjusted Operating Income Ratio | 18.6% | 20.0% | 19.4% | 22.4% | ||
| Persistency: | ||||||
| Group Long-term Disability | 92.3% | 92.4% | ||||
| Group Life | 88.6% | 83.6% | ||||
| Supplemental | 90.4% | 91.0% | ||||
| 1Excludes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. | ||||||
| N.M. = not a meaningful percentage |
110
Premium income was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 primarily due to in-force block growth.
Net investment income was higher in the third quarter of 2024 compared to the same period of 2023 primarily due to higher yield on invested assets, partially offset by lower investment income from inflation-index linked bonds. Net investment income was lower in the first nine months of 2024 compared to the same period of 2023 primarily due to lower investment income from inflation index-linked bonds, partially offset by increases in the yield on invested assets. Our investments in inflation index-linked bonds support the claim liabilities associated with certain group policies that provide for inflation-linked increases in policy benefits. The change in net investment income attributable to these index-linked bonds is partially offset by a change in policy benefits related to the inflation index-linked group long-term disability and group life policies.
The benefit ratio, excluding the impacts of reserve assumption updates, was unfavorable in the third quarter of 2024 compared to the same period of 2023 due primarily to higher incidence in the group long-term disability and group life product lines, partially offset by favorable incidence in the supplemental product line and favorable recoveries in the group long-term disability product line. The benefit ratio, excluding the impacts of reserve assumption updates, was favorable in the first nine months of 2024 compared to the same period of 2023 due primarily to favorable incidence in the supplemental product line and favorable recoveries in the group long-term disability product line, partially offset by higher incidence in the group long-term disability and group life product lines.
Commissions were higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 primarily due to in-force block growth.
The deferral of acquisition costs and the amortization of deferred acquisition costs were generally consistent in the third quarter and first nine months of 2024 compared to the same periods of 2023. The other expense ratio was lower in the third quarter of 2024 compared to the same period of 2023 due primarily to our focus on operating efficiencies, and was generally consistent in the first nine months of 2024 compared to the same period of 2023.
Sales
(in millions of dollars and pounds)
| Unum International Sales by Product Unum UK | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Group Long-term Disability | $8.4 | (5.6)% | $8.9 | $40.3 | 3.3% | $39.0 |
| Group Life | 17.0 | 61.9 | 10.5 | 53.1 | 6.6 | 49.8 |
| Supplemental | 4.8 | 26.3 | 3.8 | 30.1 | 25.4 | 24.0 |
| Unum Poland | 8.0 | 14.3 | 7.0 | 24.6 | 3.4 | 23.8 |
| Total Sales | $38.2 | 26.5 | $30.2 | $148.1 | 8.4 | $136.6 |
| Unum International Sales by Market Sector | ||||||
| Unum UK | ||||||
| Group Long-term Disability and Group Life | ||||||
| Core Market (< 500 employees) | $10.0 | (15.3)% | $11.8 | $30.7 | (23.8)% | $40.3 |
| Large Case Market | 15.4 | 102.6 | 7.6 | 62.7 | 29.3 | 48.5 |
| Subtotal | 25.4 | 30.9 | 19.4 | 93.4 | 5.2 | 88.8 |
| Supplemental | 4.8 | 26.3 | 3.8 | 30.1 | 25.4 | 24.0 |
| Unum Poland | 8.0 | 14.3 | 7.0 | 24.6 | 3.4 | 23.8 |
| Total Sales | $38.2 | 26.5 | $30.2 | $148.1 | 8.4 | $136.6 |
| Unum UK Sales by Product | ||||||
| Group Long-term Disability | £6.4 | (8.6)% | £7.0 | £31.7 | 1.3% | £31.3 |
| Group Life | 12.9 | 55.4 | 8.3 | 41.5 | 3.5 | 40.1 |
| Supplemental | 3.8 | 31.0 | 2.9 | 23.8 | 23.3 | 19.3 |
| Total Sales | £23.1 | 26.9 | £18.2 | £97.0 | 6.9 | £90.7 |
| Unum UK Sales by Market Sector | ||||||
| Group Long-term Disability and Group Life | ||||||
| Core Market (< 500 employees) | £7.7 | (18.1)% | £9.4 | £24.1 | (25.8)% | £32.5 |
| Large Case Market | 11.6 | 96.6 | 5.9 | 49.1 | 26.2 | 38.9 |
| Subtotal | 19.3 | 26.1 | 15.3 | 73.2 | 2.5 | 71.4 |
| Supplemental | 3.8 | 31.0 | 2.9 | 23.8 | 23.3 | 19.3 |
| Total Sales | £23.1 | 26.9 | £18.2 | £97.0 | 6.9 | £90.7 |
The following discussion of sales results relates only to our Unum UK product lines and is based on functional currency.
Group long-term disability sales decreased in the third quarter of 2024 compared to the same period of 2023, driven primarily by lower sales to new customers in the core market, which we define as employee groups with less than 500 employees, partially offset by higher sales to new customers in the large case market. Group long-term disability sales were higher in the first nine months of 2024 compared to the same period of 2023 driven by higher sales to new and existing customers in the large case market, partially offset by lower sales to new and existing customers in the core market.
Group life sales increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due to higher sales to new and existing customers in the large case market. Partially offsetting the increase in group life sales for the first nine months of 2024 compared to the same period of 2023 is lower sales to new and existing customers in the core market.
Supplemental sales increased in the third quarter and first nine months of 2024 compared to the same period of 2023 due to higher sales in our dental product line. Also impacting the supplemental sales comparison for the first nine months of 2024 compared to the same period of 2023 is lower sales in our group critical illness product line.
We are committed to driving growth in the Unum International segment and will build on the capabilities that we believe will generate growth and profitability in our businesses over the long term. In 2024, we will focus on scaling our business and broadening our product portfolio. For our Unum UK line of business, achieving growth remains a priority, and we will continue to focus on delivering a best in class health and wellbeing service to improve retention of our key customers and drive growth across our product offerings. We will also accelerate premium growth by focusing on both the broker experience and customer engagement, while maintaining our disciplined approach to pricing. Within our Unum Poland line of business, we will drive growth by expanding our distribution and the direct to employer channel. We will also continue to invest in digital capabilities, technology, and product enhancements which we believe will drive sustainable growth over the long term.
In 2024, we expect sales and premium growth to continue, alongside stable claim experience. We recognize that 2023 earnings benefited from inflation linked income, which we expect will continue to decrease in 2024 and could pressure earnings growth. We may see impacts to net investment income and fluctuations in our benefit ratio as inflation continues to moderate. We continuously monitor key indicators to assess our risks and adjust our business plans accordingly.
Colonial Life Segment
The Colonial Life segment includes insurance for accident, sickness, and disability products, which includes dental and vision products, life products, and cancer and critical illness products. These products are marketed to employees, on both a group and an individual basis, at the workplace through an independent contractor agent sales force and brokers.
Operating Results
Shown below are financial results and key performance indicators for the Colonial Life segment.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Accident, Sickness, and Disability | $240.6 | 1.6% | $236.7 | $725.5 | 2.5% | $708.0 |
| Life | 113.1 | 6.5 | 106.2 | 342.6 | 7.7 | 318.1 |
| Cancer and Critical Illness | 88.2 | (0.1) | 88.3 | 266.9 | 0.6 | 265.2 |
| Total Premium Income | 441.9 | 2.5 | 431.2 | 1,335.0 | 3.4 | 1,291.3 |
| Net Investment Income | 39.6 | 0.8 | 39.3 | 119.4 | 4.2 | 114.6 |
| Other Income | 0.4 | 33.3 | 0.3 | 3.6 | N.M. | 0.9 |
| Total | 481.9 | 2.4 | 470.8 | 1,458.0 | 3.6 | 1,406.8 |
| Benefits and Expenses | ||||||
| Policy Benefits | 218.1 | (0.4) | 218.9 | 667.7 | 1.2 | 660.0 |
| Policy Benefits - Remeasurement Gain | (53.9) | (38.5) | (87.7) | (73.0) | (21.6) | (93.1) |
| Commissions | 93.0 | 4.7 | 88.8 | 282.2 | 5.8 | 266.7 |
| Deferral of Acquisition Costs | (77.1) | 2.8 | (75.0) | (234.7) | 3.8 | (226.1) |
| Amortization of Deferred Acquisition Costs | 55.6 | (1.9) | 56.7 | 163.9 | 6.8 | 153.4 |
| Other Expenses | 86.8 | 1.5 | 85.5 | 261.9 | 3.6 | 252.9 |
| Total | 322.5 | 12.3 | 287.2 | 1,068.0 | 5.3 | 1,013.8 |
| Income Before Income Tax and Net Investment Gains and Losses | 159.4 | (13.2) | 183.6 | 390.0 | (0.8) | 393.0 |
| Reserve Assumption Updates | (46.0) | (43.0) | (80.7) | (46.0) | (43.0) | (80.7) |
| Adjusted Operating Income | $113.4 | 10.2 | $102.9 | $344.0 | 10.2 | $312.3 |
| Operating Ratios (% of Premium Income): | ||||||
| Benefit Ratio1 | 47.6% | 49.1% | 48.0% | 50.2% | ||
| Other Expense Ratio | 19.6% | 19.8% | 19.6% | 19.6% | ||
| Income Ratio | 36.1% | 42.6% | 29.2% | 30.4% | ||
| Adjusted Operating Income Ratio | 25.7% | 23.9% | 25.8% | 24.2% | ||
| Persistency: | ||||||
| Accident, Sickness, and Disability | 73.3% | 73.1% | ||||
| Life | 84.3% | 84.7% | ||||
| Cancer and Critical Illness | 81.8% | 82.2% | ||||
| 1Excludes the reserve assumption updates that occurred during the third quarters of 2024 and 2023. | ||||||
| N.M. = not a meaningful percentage |
114
Premium income in the third quarter and first nine months of 2024 was favorable compared to the same periods of 2023 due to higher prior period sales and generally stable persistency. Net investment income was generally consistent in the third quarter of 2024 relative to the same period of 2023. Net investment income increased during the first nine months of 2024 relative to the same period of 2023 due primarily to an increase in the yield on invested assets.
The benefit ratio, excluding the impacts of the reserve assumption updates, was favorable in the third quarter and first nine months of 2024 relative to the same periods of 2023 primarily due to favorable benefit experience in the cancer and critical illness and life product lines. Also impacting the comparison for the first nine months of 2024 compared to 2023 was favorable benefit experience in the accident, sickness, and disability product line.
Commissions and the deferral of acquisition costs were higher in the third quarter and first nine months of 2024 relative to the same periods of 2023 due to higher sales in prior periods. The amortization of deferred acquisition costs was generally consistent in the third quarter of 2024 relative to the same period of 2023. The amortization of deferred acquisition costs was higher during the first nine months of 2024 relative to the same period of 2023 primarily due to growth in the level of the deferred asset. The other expense ratio was generally consistent in the third quarter and first nine months of 2024 relative to the same periods of 2023.
Sales
(in millions of dollars)
| Sales by Product | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Accident, Sickness, and Disability | $74.7 | 2.2% | $73.1 | $215.1 | 0.3% | $214.5 |
| Life | 28.5 | (4.7) | 29.9 | 83.1 | (3.7) | 86.3 |
| Cancer and Critical Illness | 17.7 | (3.3) | 18.3 | 48.6 | (1.4) | 49.3 |
| Total Sales | $120.9 | (0.3) | $121.3 | $346.8 | (0.9) | $350.1 |
| Sales by Market Sector | ||||||
| Commercial Sector | ||||||
| Core Market (< 1,000 employees) | $69.9 | (9.5)% | $77.2 | $220.4 | (4.8)% | $231.6 |
| Large Case Market | 16.0 | 52.4 | 10.5 | 37.3 | 15.5 | 32.3 |
| Subtotal | 85.9 | (2.1) | 87.7 | 257.7 | (2.3) | 263.9 |
| Public Sector | 35.0 | 4.2 | 33.6 | 89.1 | 3.4 | 86.2 |
| Total Sales | $120.9 | (0.3) | $121.3 | $346.8 | (0.9) | $350.1 |
Commercial sector sales decreased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to lower sales to new and existing customers in the core market, which we define as accounts with less than 1,000 employees, partially offset by higher sales to new customers in the large case market. Public sector sales increased in the third quarter and first nine months of 2024 compared to the same periods of 2023 due to higher sales to new customers.
We remain committed to providing employees and their families with simple, modern, and personal benefit solutions. During 2024, we will continue to utilize our strong distribution system of independent agents, benefit counselors and broker partnerships. We will also continue to invest in solutions and digital capabilities to expand our reach and effectiveness, driving growth and improving productivity while enhancing the customer experience. In 2024, we will continue to bring an enhanced engagement and enrollment platform to market, enabling deeper connections with employees through the enrollment process as well as maintaining stronger relationships throughout the customer lifecycle. We believe our distribution system, customer service capabilities, digital and virtual tools, and ability to serve all market sizes position us well for future growth.
In 2024, we expect strong growth in adjusted operating income for the full year with premium growth increasing from the prior year. We expect improved claim experience in 2024 but could continue to experience some level of claims volatility. While we believe our underlying profitability will remain strong, current economic conditions and increasing competition in the voluntary workplace market are risks to achievement of our business plans. We continuously monitor key indicators to assess our risks and adjust our business plans accordingly.
Closed Block Segment
The Closed Block segment consists of group and individual long-term care and other insurance products no longer actively marketed. We discontinued offering individual long-term care in 2009 and group long-term care in 2012. Other insurance products include individual disability, group pension, individual life and corporate-owned life insurance, reinsurance pools and management operations, and other miscellaneous product lines.
Operating Results
Shown below are financial results and key performance indicators for the Closed Block segment.
(in millions of dollars, except ratios)
| Adjusted Operating Revenue Premium Income | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Long-term Care | $173.7 | 0.9% | $172.1 | $521.5 | 0.1% | $521.2 |
| All Other | 43.1 | (20.6) | 54.3 | 140.9 | (15.1) | 166.0 |
| Total Premium Income | 216.8 | (4.2) | 226.4 | 662.4 | (3.6) | 687.2 |
| Net Investment Income | 284.3 | 3.4 | 274.9 | 851.6 | 7.0 | 796.0 |
| Other Income | 12.4 | (3.1) | 12.8 | 37.7 | (6.0) | 40.1 |
| Total | 513.5 | (0.1) | 514.1 | 1,551.7 | 1.9 | 1,523.3 |
| Benefits and Expenses | ||||||
| Policy Benefits | 407.8 | 0.8 | 404.4 | 1,237.4 | 2.9 | 1,202.8 |
| Policy Benefits - Remeasurement Loss (Gain) | (149.5) | (137.1) | 402.5 | (102.8) | (124.4) | 421.3 |
| Commissions | 17.8 | (2.7) | 18.3 | 52.0 | (6.3) | 55.5 |
| Other Expenses | 44.3 | 1.1 | 43.8 | 131.0 | 2.0 | 128.4 |
| Total | 320.4 | (63.1) | 869.0 | 1,317.6 | (27.1) | 1,808.0 |
| Income (Loss) Before Income Tax and Net Investment Gains and Losses | 193.1 | 154.4 | (354.9) | 234.1 | 182.2 | (284.7) |
| Amortization of the Cost of Reinsurance | 10.4 | (6.3) | 11.1 | 31.1 | (6.0) | 33.1 |
| Non-Contemporaneous Reinsurance | 6.0 | (34.8) | 9.2 | 20.2 | (23.5) | 26.4 |
| Reserve Assumption Updates - Long-term Care | (174.1) | (147.3) | 368.1 | (174.1) | (147.3) | 368.1 |
| Reserve Assumption Updates - All Other | (1.2) | N.M. | 0.7 | (1.2) | N.M. | 0.7 |
| Adjusted Operating Income | $34.2 | — | $34.2 | $110.1 | (23.3) | $143.6 |
| Long-term Care Net Premium Ratio | 94.5% | 93.4% | ||||
| Operating Ratios (% of Premium Income): | ||||||
| Other Expense Ratio1 | 15.6% | 14.4% | 15.1% | 13.9% | ||
| Income Ratio | 89.1% | (156.8)% | 35.3% | (41.4)% | ||
| Adjusted Operating Income Ratio | 15.8% | 15.1% | 16.6% | 20.9% | ||
| Long-term Care Persistency | 95.2% | 95.5% | ||||
| 1Excludes amortization of the cost of reinsurance. | ||||||
| N.M. = not a meaningful percentage |
Premium income for the long-term care product line in the third quarter and first nine months of 2024 was generally consistent with the same periods of 2023. Premium income for our all other product line continues to decline as expected due to policyholder lapses.
Net investment income was higher during the third quarter and first nine months of 2024 relative to the same periods of 2023 primarily due to an increase in the level of invested assets. Also impacting the comparison for the first nine months of 2024 relative to the same period of 2023 was higher miscellaneous investment income, primarily related to larger increases in the NAV on our private equity partnerships.
Other income primarily includes the underlying results and associated net investment income of certain assumed blocks of business.
Policy benefits including remeasurement loss (gain), excluding the impacts of the reserve assumption updates and non-contemporaneous reinsurance, were generally consistent during the third quarter of 2024 relative to the same period of 2023. Policy benefits including remeasurement loss (gain), excluding the impacts of the reserve assumption updates and non-contemporaneous reinsurance, were unfavorable in the first nine months of 2024 relative to the same period of 2023 driven primarily by the increase in the current period benefit expense resulting from the higher net premium ratio and the impact of capped cohorts in the long-term care product line. The net premium ratio for long-term care increased to 94.5 percent at September 30, 2024 from 93.4 percent at September 30, 2023 due primarily to policyholder terminations and the assumption updates in the third quarter of 2024.
The other expense ratio, excluding the amortization of the cost of reinsurance, was higher in the third quarter and first nine months of 2024 compared to the same periods of 2023 due primarily to an increase in operational investments in our business and a decline in expense allowances related to the ceded block of individual disability business. Also contributing to the higher other expense ratio, excluding the amortization of the cost of reinsurance, in the first nine months of 2024 compared to the same period of 2023 was an increase in employee-related costs.
Individual Disability Reinsurance Transaction
As shown in the chart above, we exclude from income before income tax and net investment gains and losses, the amortization of the cost of reinsurance and the impact of non-contemporaneous reinsurance related to the Closed Block individual disability reinsurance transaction, where we ceded a significant portion of this business. The cost of reinsurance continues to be amortized over a period of approximately 22 years, on a declining trajectory generally consistent with the expected run-off pattern of the ceded reserves. As a result of the execution of the second phase of the reinsurance transaction occurring after January 1, 2021, the transition date of ASU 2018-12, in accordance with the provisions of the ASU related to non-contemporaneous reinsurance, we were required to establish the ceded reserves using an upper-medium grade fixed-income instrument as of the reinsurance transaction date in March 2021 which resulted in higher ceded reserves compared to that which was reported historically. However, the direct reserves for the block reinsured in the second phase were calculated using the original discount rate utilized as of the transition date. Both the direct and ceded reserves are then remeasured at each reporting period using a current discount rate reflective of an upper-medium grade fixed-income instrument, with the changes recognized in OCI. While the total equity impact is neutral, the different original discount rates utilized for direct and ceded reserves result in disproportionate earnings impacts. The impact of non-contemporaneous reinsurance will fluctuate depending on the magnitude of reserve changes during the period. The decrease in the effects of non-contemporaneous reinsurance treatment in the third quarter and first nine months of 2024 compared to the same periods of 2023 is due to expected run out of the ceded block which resulted in a smaller net change in reserves in the third quarter and first nine months of 2024 compared to the same periods of 2023.
We will continue to execute on our well-defined strategy of implementing long-term care premium rate increases, efficient capital management, improved financial analysis, and operational effectiveness. We will continue to explore structural options to enhance financial flexibility. We continue to file requests with various state insurance departments for premium rate increases on certain of our individual and group long-term care policies which reflect assumptions as of the date of filings. In states for which a rate increase is submitted and approved, we routinely provide customers options for coverage changes or other approaches that might fit their current financial and insurance needs. Despite continued anticipated premium rate increases in our long-term care business, we expect overall premium income and adjusted operating revenue to decline over the long term as these closed blocks of business wind down. We will likely experience volatility in net investment income due to fluctuations of miscellaneous investment income, driven by the allocation towards alternative assets, primarily private equity partnership investments, in the long-term care product line portfolio. We record changes in our share of the NAV of the partnerships in net investment income. We receive financial information related to our investments in partnerships and generally record investment income on a one-quarter lag in accordance with our accounting policy. As these net asset values are volatile and can fluctuate materially with changes in market economic conditions, there may possibly be significant movements up or down in future periods as conditions change. We continuously monitor key indicators to assess our risks and adjust our business plans, including utilization of derivative financial instruments to manage interest rate risk.
Profitability of our long-tailed products is affected by claims experience related to mortality and morbidity, resolutions, investment returns, premium rate increases, and persistency. The net premium ratio represents the ratio of future expected benefits and related expenses to future expected gross premiums using the original discount rate. The long-term care benefits experience may continue to have quarterly volatility, particularly in the near term as our claim block matures and as we continue the implementation of premium rate increases. Claim resolution rates which reflect the probability that a disability or long-term care claim will close due to recovery or death of the insureds, are very sensitive to operational and external factors and can be volatile. Our claim resolution rate assumption used in determining reserves is our expectation of the resolution rate we will experience over the life of the block of business and will vary from actual experience in any one period. It is possible that variability in any of our reserve assumptions, including, but not limited to, mortality, morbidity, resolutions, premium rate increases, benefit change elections, and persistency, could result in a material impact to our reserves.
As a result of the execution of the reinsurance transaction related to our Closed Block individual disability line of business, we have fully ceded a significant portion of this business. We expect that earnings will continue to be impacted by the amortization of the cost of reinsurance and the impacts of non-contemporaneous reinsurance, but we anticipate these impacts will decline over time with the run-off pattern of the reserves.
For further discussion of ASU 2018-12, see Note 2 of the “Notes to the Consolidated Financial Statements” contained herein in Item 1.
Corporate Segment
The Corporate segment includes investment income on corporate assets not specifically allocated to a line of business, interest expense on corporate debt, and certain other corporate income and expenses not allocated to a line of business.
Operating Results
(in millions of dollars)
| Adjusted Operating Revenue | Three Months Ended September 30 2024 | % Change | 2023 | Nine Months Ended September 30 2024 | % Change | 2023 |
|---|---|---|---|---|---|---|
| Net Investment Income | $12.5 | (31.7)% | $18.3 | $44.8 | (35.8)% | $69.8 |
| Other Income | — | — | — | 1.1 | (56.0) | 2.5 |
| Total | 12.5 | (31.7) | 18.3 | 45.9 | (36.5) | 72.3 |
| Interest, Debt, and Other Expenses | 77.2 | 29.1 | 59.8 | 202.0 | 10.9 | 182.2 |
| Loss Before Income Tax and Net Investment Gains and Losses | (64.7) | 55.9 | (41.5) | (156.1) | 42.0 | (109.9) |
| Loss on Legal Settlement | 15.3 | 100.0 | — | 15.3 | 100.0 | — |
| Adjusted Operating Loss | $(49.4) | 19.0 | $(41.5) | $(140.8) | 28.1 | $(109.9) |
Adjusted operating loss, excluding the loss on legal settlement, increased in the third quarter and first nine months of 2024 relative to the same periods of 2023 due primarily to decreased net investment income, which was driven by increased allocations to our lines of business. See "Executive Summary" contained herein this Item 2 and Note 14 of the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further discussion on the loss on legal settlement.
We expect to continue to generate excess capital on an annual basis through the statutory earnings in our insurance subsidiaries and believe we are well positioned with flexibility to preserve our capital strength while also returning capital to our shareholders. We may experience volatility in net investment income due to changes in the prevailing interest rates as well as both the composition and level of invested assets.
Investments
Overview
Investment activities are an integral part of our business, and profitability is significantly affected by investment results. We segment our invested assets into portfolios that support our various product lines. Generally, our investment strategy for our portfolios is to match the effective asset cash flows and durations with related expected liability cash flows and durations to consistently meet the liability funding requirements of our businesses and to manage interest rate risk. We seek to earn investment income while assuming credit risk in a prudent and selective manner, subject to constraints of quality, liquidity, diversification, and regulatory considerations. Our overall investment philosophy is to invest in a portfolio of high quality assets that provide investment returns consistent with that assumed in the pricing of our insurance products. Assets are invested predominantly in fixed maturity securities.
We may redistribute investments among our different lines of business or sell selected securities and reinvest the proceeds, when necessary, to adjust the cash flow and/or duration of the asset portfolios to better match the cash flow and duration of the liability portfolios. Asset and liability portfolio modeling is updated on a quarterly basis and is used as part of the overall interest rate risk management strategy. Cash flows from the in-force asset and liability portfolios are projected at current interest rate levels and at levels reflecting an increase and a decrease in interest rates to obtain a range of projected cash flows under the different interest rate scenarios. These results enable us to assess the impact of projected changes in cash flows and duration resulting from potential changes in interest rates. Testing the asset and liability portfolios under various interest rate scenarios enables us to choose what we believe to be the most appropriate investment strategy, as well as to limit the risk of disadvantageous outcomes. Although we test the asset and liability portfolios under various interest rate scenarios as part of our modeling, the majority of our liabilities related to insurance contracts are not interest rate sensitive, and we therefore have minimal exposure to policy withdrawal risk. Our determination of investment strategy relies on long-term measures such as asset adequacy analysis and the relationship between the portfolio yields supporting our various product lines and the aggregate discount rate assumptions embedded in the reserves. We also use this analysis in determining hedging strategies and utilizing derivative financial instruments for managing interest rate risk and the risk related to matching duration for our assets and liabilities. We do not use derivative financial instruments for speculative purposes.
Our investment portfolio is well diversified by type of investment and industry sector. We have established an investment strategy that we believe will provide for adequate cash flows from operations and allow us to hold our securities through periods where significant decreases in fair value occur. We believe our emphasis on risk management in our investment portfolio has positioned us well and generally reduced the volatility in our results.
Fixed Maturity Securities
The fair values and associated unrealized gains and losses of our fixed maturity securities portfolio, by industry classification, are as follows:
Fixed Maturity Securities - By Industry Classification
As of September 30, 2024
(in millions of dollars)
| Classification | Fair Value | Net Unrealized Gain (Loss) | Fair Value with Gross Unrealized Loss | Gross Unrealized Loss | Fair Value with Gross Unrealized Gain | Gross Unrealized Gain |
|---|---|---|---|---|---|---|
| Basic Industry | $2,611.1 | $(46.8) | $1,395.2 | $120.9 | $1,215.9 | $74.1 |
| Capital Goods | 3,410.9 | (18.5) | 1,592.6 | 151.1 | 1,818.3 | 132.6 |
| Communications | 2,295.2 | (20.8) | 998.9 | 148.6 | 1,296.3 | 127.8 |
| Consumer Cyclical | 1,482.7 | (55.0) | 861.6 | 95.4 | 621.1 | 40.4 |
| Consumer Non-Cyclical | 6,703.8 | (199.5) | 3,578.6 | 428.7 | 3,125.2 | 229.2 |
| Energy | 2,644.8 | 76.9 | 955.3 | 72.0 | 1,689.5 | 148.9 |
| Financial Institutions | 4,012.2 | (223.5) | 2,757.8 | 285.8 | 1,254.4 | 62.3 |
| Mortgage/Asset-Backed | 850.6 | (3.2) | 385.6 | 16.4 | 465.0 | 13.2 |
| Sovereigns | 850.1 | (114.7) | 371.0 | 137.1 | 479.1 | 22.4 |
| Technology | 1,533.7 | (81.4) | 1,063.7 | 102.3 | 470.0 | 20.9 |
| Transportation | 1,719.3 | (71.1) | 999.0 | 117.7 | 720.3 | 46.6 |
| U.S. Government Agencies and Municipalities | 4,083.9 | (302.0) | 2,444.8 | 449.5 | 1,639.1 | 147.5 |
| Public Utilities | 5,585.2 | 23.4 | 1,895.1 | 248.9 | 3,690.1 | 272.3 |
| Total | $37,783.5 | $(1,036.2) | $19,299.2 | $2,374.4 | $18,484.3 | $1,338.2 |
122
The following two tables show the length of time our investment-grade and below-investment-grade fixed maturity securities portfolios had been in a gross unrealized loss position as of September 30, 2024 and at the end of the prior four quarters. The relationships of the current fair value to amortized cost are not necessarily indicative of the fair value to amortized cost relationships for the securities throughout the entire time that the securities have been in an unrealized loss position nor are they necessarily indicative of the relationships after September 30, 2024. The decrease in the net unrealized loss on fixed maturity securities during the third quarter of 2024 was due primarily to a decrease in U.S. Treasury rates.
Unrealized Loss on Investment-Grade Fixed Maturity Securities
Length of Time in Unrealized Loss Position
(in millions of dollars)
| Fair Value < 100% >= 70% of Amortized Cost | 2024 September 30 | June 30 | March 31 | 2023 December 31 | September 30 |
|---|---|---|---|---|---|
| <= 90 days | $11.8 | $31.4 | $48.0 | $8.3 | $242.2 |
| > 90 <= 180 days | 1.2 | 74.6 | 8.3 | 3.5 | 152.4 |
| > 180 <= 270 days | 5.1 | 28.6 | 4.5 | 16.4 | 79.2 |
| > 270 days <= 1 year | 3.3 | 6.4 | 22.3 | 18.9 | 5.5 |
| > 1 year <= 2 years | 24.9 | 286.2 | 518.7 | 1,536.4 | 2,307.7 |
| > 2 years <= 3 years | 1,708.4 | 2,019.4 | 1,721.0 | 675.6 | 195.4 |
| > 3 years | 202.0 | 60.8 | 63.7 | 22.4 | 6.8 |
| Sub-total | 1,956.7 | 2,507.4 | 2,386.5 | 2,281.5 | 2,989.2 |
| Fair Value < 70% >= 40% of Amortized Cost | |||||
| <= 90 days | — | 0.1 | — | — | — |
| > 270 days <= 1 year | — | — | — | — | 34.9 |
| > 1 year <= 2 years | 28.4 | 33.3 | 34.1 | 99.5 | 1,180.0 |
| > 2 years <= 3 years | 232.8 | 597.2 | 439.5 | 232.3 | 157.5 |
| > 3 years | 62.3 | 61.8 | 56.9 | 22.0 | 15.7 |
| Sub-total | 323.5 | 692.4 | 530.5 | 353.8 | 1,388.1 |
| Fair Value <= 40% of Amortized Cost | |||||
| > 1 year <= 2 years | — | — | 23.3 | 22.3 | 26.7 |
| > 2 years <= 3 years | 28.6 | 27.2 | 2.8 | 2.7 | — |
| Sub-total | 28.6 | 27.2 | 26.1 | 25.0 | 26.7 |
| Total | $2,308.8 | $3,227.0 | $2,943.1 | $2,660.3 | $4,404.0 |
123
Unrealized Loss on Below-Investment-Grade Fixed Maturity Securities
Length of Time in Unrealized Loss Position
(in millions of dollars)
| Fair Value < 100% >= 70% of Amortized Cost | 2024 September 30 | June 30 | March 31 | 2023 December 31 | September 30 |
|---|---|---|---|---|---|
| <= 90 days | $0.3 | $0.4 | $0.2 | $0.3 | $3.7 |
| > 90 <= 180 days | — | 0.7 | 0.8 | — | 2.4 |
| > 180 <= 270 days | — | 0.9 | — | 0.2 | 1.4 |
| > 270 days <= 1 year | — | — | 0.2 | 0.1 | — |
| > 1 year <= 2 years | — | 0.9 | 7.2 | 51.6 | 106.7 |
| > 2 years <= 3 years | 38.6 | 51.7 | 45.6 | 7.3 | 3.9 |
| > 3 years | 11.7 | — | 0.1 | 0.1 | 2.7 |
| Sub-total | 50.6 | 54.6 | 54.1 | 59.6 | 120.8 |
| Fair Value < 70% >= 40% of Amortized Cost | |||||
| > 1 year <= 2 years | — | — | 13.9 | 26.4 | 27.7 |
| > 2 years <= 3 years | 14.7 | 25.6 | 13.5 | — | — |
| > 3 years | — | 12.3 | 12.5 | 12.9 | 15.1 |
| Sub-total | 14.7 | 37.9 | 39.9 | 39.3 | 42.8 |
| Fair Value <= 40% of Amortized Cost | |||||
| > 1 year <= 2 years | — | 0.1 | 0.1 | 4.5 | 10.5 |
| > 3 years | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| Sub-total | 0.3 | 0.3 | 0.3 | 4.7 | 10.7 |
| Total | $65.6 | $92.8 | $94.3 | $103.6 | $174.3 |
124
As of September 30, 2024, we held 23 investment-grade fixed maturity securities with a gross unrealized loss of $10.0 million or greater as shown in the chart below.
Gross Unrealized Losses $10 Million or Greater on Investment-Grade Fixed Maturity Securities
As of September 30, 2024
(in millions of dollars)
| Classification | Fair Value | Gross Unrealized Loss | Numbers of Issuers |
|---|---|---|---|
| Basic Industry | $46.6 | $(11.0) | 1 |
| Capital Goods | 45.4 | (11.2) | 1 |
| Communications | 312.0 | (65.9) | 5 |
| Consumer Cyclical | 78.6 | (18.4) | 1 |
| Consumer Non-Cyclical | 76.2 | (17.6) | 1 |
| Financial Institutions | 208.9 | (35.8) | 3 |
| Sovereigns | 325.2 | (122.8) | 2 |
| Transportation | 109.6 | (34.7) | 3 |
| U.S. Government Agencies and Municipalities | 35.9 | (10.3) | 1 |
| Public Utilities | 275.2 | (66.0) | 5 |
| Total | $1,513.6 | $(393.7) | 23 |
At September 30, 2024, we held one below investment-grade fixed maturity security with a gross unrealized loss greater than $10.0 million. The security is a utilities company and had a fair value of $34.2 million and a gross unrealized loss of $11.2 million.
Unrealized losses on investment-grade fixed maturity securities principally relate to changes in interest rates or changes in market or sector credit spreads which occurred subsequent to the acquisition of the securities. Below-investment-grade fixed maturity securities are generally more likely to develop credit concerns than investment-grade securities. At September 30, 2024, the unrealized losses in our below-investment-grade fixed maturity securities were generally due to higher interest rates, credit spreads in certain industries or sectors and, to a lesser extent, credit concerns related to specific securities. For each specific security in an unrealized loss position, we believe that there are positive factors which mitigate credit concerns and that the securities for which we have not recorded a credit loss will recover in value. We have the ability and intent to continue to hold these securities to recovery of amortized cost less allowance for credit losses.
We had no individual net investment losses of $10.0 million or greater from credit losses or sales of fixed maturity securities during the first nine months of 2024 or 2023.
As of September 30, 2024, the amortized cost net of allowance for credit losses and fair value of our below-investment-grade fixed maturity securities was $1,531.9 million and $1,496.3 million, respectively, and our below-investment-grade fixed maturity securities as a percentage of our total investment portfolio decreased to 3.2 percent at September 30, 2024 from 3.3 percent at December 31, 2023 on a fair value basis. Below-investment-grade securities are inherently riskier than investment-grade securities since the risk of default by the issuer, by definition and as exhibited by bond rating, is higher. Also, the secondary market for certain below-investment-grade issues can be highly illiquid. Additional downgrades may occur, but we do not anticipate any liquidity problems resulting from our investments in below-investment-grade securities, nor do we expect these investments to adversely affect our ability to hold our other investments to maturity.
Fixed Maturity Securities - Foreign Exposure
Our investments in issuers in foreign countries are chosen for specific portfolio management purposes, including asset and liability management and portfolio diversification across geographic lines and sectors to minimize non-market risks. In our approach to investing in fixed maturity securities, specific investments within approved countries and industry sectors are evaluated for their market position and specific strengths and potential weaknesses. For each security, we consider the political, legal, and financial environment of the sovereign entity in which an issuer is domiciled and operates. The country of domicile is based on consideration of the issuer's headquarters, in addition to location of the assets and the country in which the majority of sales and earnings are derived. We do not have exposure to foreign currency risk, as the cash flows from these investments are either denominated in currencies or hedged into currencies to match the related liabilities. We continually evaluate our foreign investment risk exposure.
Mortgage Loans
The carrying value of our mortgage loan portfolio was $2,238.9 million and $2,318.2 million at September 30, 2024 and December 31, 2023, respectively. Our investments in mortgage loans are carried at amortized cost less an allowance for expected credit losses which was $16.5 million and $10.2 million at September 30, 2024 and December 31, 2023, respectively. Our mortgage loan portfolio is comprised entirely of commercial mortgage loans. Our mortgage loan portfolio is well diversified geographically and among property types.
Due to conservative underwriting, the incidence of non-performing mortgage loans and foreclosure activity continues to be low. Other than our allowance for expected credit losses, we held no specifically identified impaired mortgage loans at September 30, 2024 or December 31, 2023. See Note 4 in the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further discussion of our mortgage loan portfolio and the allowance for expected credit losses.
Private Equity Partnerships
The carrying value of our investments in private equity partnerships was $1,428.0 million and $1,326.2 million at September 30, 2024 and December 31, 2023, respectively. These partnerships are passive in nature and represent funds that are primarily invested in private credit, private equity, and real assets. The carrying value of the partnerships is based on our share of the partnership's NAV and changes in the carrying value are recorded as a component of net investment income. We receive financial information related to our investments in partnerships and generally record investment income on a one-quarter lag in accordance with our accounting policy. We recorded net investment income totaling $19.6 million and $72.6 million for the partnerships in the third quarter and first nine months of 2024, respectively. The majority of our investments in partnerships are not redeemable. Distributions received from the funds arise from income generated by the underlying investments as well as the liquidation of the underlying investments. There is generally not a public market for these investments. We had $805.6 million of commitments for additional investments in the partnerships at September 30, 2024 which may or may not be funded. See Note 3 in the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further discussion of our private equity partnerships.
Derivative Financial Instruments
We use derivative financial instruments primarily to manage interest rate risk, risk related to matching duration for our assets and liabilities, foreign currency risk, and equity risk. Historically, we have utilized current and forward interest rate swaps, current and forward currency swaps, forward benchmark interest rate locks, currency forward contracts, forward contracts on specific fixed income securities, and total return swaps. During the first nine months of 2024, we entered into $806 million of notional forward U.S. Treasury interest rate locks in our long-term care product line to manage our reinvestment risk. Credit exposure on derivatives is limited to the value of those contracts in a net gain position, including accrued interest receivable less collateral held. Our credit exposure was $0.3 million at September 30, 2024. At September 30, 2024, the carrying value of fixed maturity securities and cash collateral received from our counterparties was $30.9 million and $3.4 million, respectively. The carrying value of fixed maturity securities posted as collateral to our counterparties was $50.6 million at September 30, 2024. There was no cash posted as collateral to our counterparties at September 30, 2024. We believe that our credit risk is mitigated by our use of multiple counterparties, all of which have an investment-grade credit rating, and by our use of cross-collateralization agreements. See Note 5 in the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further discussion of our derivatives.
Our exposure to non-current investments, defined as invested assets which are delinquent as to interest and/or principal payments, totaled $3.8 million on a fair value basis at September 30, 2024. We had no exposure to non-current investments at December 31, 2023.
For further information see "Investments" in Part I, Item 1 and "Critical Accounting Estimates" and "Investments" in Part II, Item 7 of our annual report on Form 10-K for the year ended December 31, 2023, and Notes 3, 4, and 5 of the "Notes to Consolidated Financial Statements" contained herein in Item 1.
Liquidity and Capital Resources
Overview
Our liquidity requirements are met primarily by cash flows provided from operations, principally in our insurance subsidiaries. Premium and investment income, as well as maturities and sales of invested assets, provide the primary sources of cash. Debt and/or securities offerings provide additional sources of liquidity. Cash is applied to the payment of policy benefits, costs of acquiring new business (principally commissions), operating expenses, and taxes, as well as purchases of new investments.
We have established an investment strategy that we believe will provide for adequate cash flows from operations. We attempt to match our asset cash flows and durations with expected liability cash flows and durations to meet the funding requirements of our business. However, deterioration in the credit market may delay our ability to sell our positions in certain of our fixed maturity securities in a timely manner and adversely impact the price we receive for such securities, which may negatively impact our cash flows. Furthermore, if we experience defaults on securities held in the investment portfolios of our insurance subsidiaries, this will negatively impact statutory capital, which could reduce our insurance subsidiaries' capacity to pay dividends to our holding companies. A reduction in dividends to our holding companies could force us to seek external financing to avoid impairing our ability to pay dividends to our stockholders or meet our debt and other payment obligations.
Our policy benefits are primarily in the form of claim payments, and we have minimal exposure to the policy withdrawal risk associated with deposit products such as individual life policies or annuities. A decrease in demand for our insurance products or an increase in the incidence of new claims or the duration of existing claims could negatively impact our cash flows from operations. However, our historical pattern of benefits paid to revenues is generally consistent, even during cycles of economic downturns, which serves to minimize liquidity risk.
The liquidity requirements of the holding company Unum Group include common stock dividends, interest and debt service, and ongoing investments in our businesses. Unum Group's liquidity requirements are met by assets held by Unum Group and our intermediate holding companies, dividends from primarily our insurance subsidiaries, and issuance of common stock, debt, or other capital securities and borrowings from our existing credit facility, as needed. As of September 30, 2024, Unum Group and our intermediate holding companies had available holding company liquidity of $1,393.0 million that was held primarily in bank deposits, commercial paper, money market funds, corporate bonds, municipal bonds and asset backed securities. No significant restrictions exist on our ability to use or access funds in any of our U.S. or foreign intermediate holding companies. Dividends repatriated from our foreign subsidiaries are eligible for 100 percent exemption from U.S. income tax but may be subject to withholding tax and/or tax on foreign currency gain or loss.
As part of our capital deployment strategy, we may repurchase shares of Unum Group's common stock, as authorized by our board of directors. The timing and amount of repurchase activity is based on market conditions and other considerations, including the level of available cash, alternative uses for cash, and our stock price. During the nine months ended September 30, 2024, we repurchased 9.7 million shares at a cost of $500.0 million excluding commissions and excise tax.
Our board of directors has authorized the following repurchase programs:
(in millions)
| Effective Date Expiration Date | July 2024 Authorization August 1, 2024 None | October 2023 Authorization1 January 1, 2024 July 31, 2024 |
|---|---|---|
| Authorized Repurchase Amount | $1,000.0 | $500.0 |
| Cost of Shares Repurchased Under Repurchase Program | 35.8 | 464.2 |
| Unused and Expired | — | 35.8 |
| Remaining Repurchase Amount at September 30, 2024 | $964.2 | $— |
1Concurrent with the announcement of the July 2024 repurchase program, we also announced the termination of the October 2023 program as of July 31, 2024, and all unused amounts under that program expired as of that date.
See Note 12 of the "Notes to Consolidated Financial Statements" contained herein in Item 1.
Cash Available from Subsidiaries
Unum Group and certain of its intermediate holding company subsidiaries depend on payments from subsidiaries to pay dividends to stockholders, to pay debt obligations, and/or to pay expenses. These payments by our insurance and non-insurance subsidiaries may take the form of dividends, operating and investment management fees, and/or interest payments on loans from the parent to a subsidiary.
Restrictions under applicable state insurance laws limit the amount of dividends that can be paid to a parent company from its insurance subsidiaries in any 12-month period without prior approval by regulatory authorities. For life insurance companies domiciled in the U.S., that limitation generally equals, depending on the state of domicile, either ten percent of an insurer's statutory surplus with respect to policyholders as of the preceding year end or the statutory net gain from operations, excluding realized capital gains and losses, of the preceding year. The payment of dividends to a parent company from a life insurance subsidiary is generally further limited to the amount of unassigned funds.
In connection with a financial examination of Unum America, which closed at the end of the second quarter of 2020, the Maine Bureau of Insurance (MBOI) concluded that Unum America’s long-term care statutory reserves were deficient by $2,100 million as of December 31, 2018, the financial statement date of the examination period. The amount reserves are deficient may increase or decrease over time based on changes in assumed reinvestment rates, policyholder inventories, premium rate increase activity, and the underlying growth in the locked in statutory reserve basis as well as updates to other long term actuarial assumptions. The MBOI granted permission to Unum America on May 1, 2020, to phase in the additional statutory reserves over seven years beginning with year-end 2020 and ending with year-end 2026. The calculation of the premium deficiency reserve (PDR) reflects specific assumptions set by the MBOI and results in significant margin above Unum America’s best estimate assumptions. As of December 31, 2023, the PDR calculated under the basis resulting from the MBOI examination was $1,604 million, which has been fully recognized. Our long-term care reserves and financial results reported under generally accepted accounting principles were not affected by the MBOI’s examination conclusion.
Unum America cedes blocks of long-term care business to Fairwind Insurance Company (Fairwind), which is an affiliated captive reinsurance subsidiary domiciled in the United States. The ability of Fairwind to pay dividends to Unum Group will depend on its satisfaction of applicable regulatory requirements and on the performance of the business reinsured by Fairwind. Fairwind did not pay dividends in 2023 nor do we anticipate that Fairwind will pay dividends in 2024. Unum Group did not make any capital contributions to Fairwind during the first nine months of 2024, nor do we expect to make capital contributions for the remainder of the year.
The ability of Unum Group and certain of its intermediate holding company subsidiaries to continue to receive dividends from their insurance subsidiaries also depends on additional factors such as RBC ratios and capital adequacy and/or solvency requirements, funding growth objectives at an affiliate level, and maintaining appropriate capital adequacy ratios to support desired ratings. The RBC ratios for our U.S. insurance subsidiaries at September 30, 2024 are in line with our expectations and are significantly above the level that would require state regulatory action.
Unum Group and/or certain of its intermediate holding company subsidiaries may also receive dividends from our U.K. subsidiaries, the payment of which may be subject to applicable insurance company regulations and capital guidance in the U.K. Unum Limited is subject to the requirements of Solvency II, a European Union (EU) directive that is part of retained UK law pursuant to the European Union (Withdrawal) Act 2018, which prescribes capital requirements and risk management standards for the European insurance industry. Our U.K. holding company is also subject to the Solvency II requirements relevant to insurance holding companies while, together with certain of its subsidiaries including Unum Limited, the group (the Unum UK Solvency II Group) is subject to group supervision under Solvency II. The Unum UK Solvency II Group received approval from the U.K. Prudential Regulation Authority (PRA) to use its own internal model for calculating regulatory capital and also received approval for certain associated regulatory permissions including transitional relief as the Solvency II capital regime continues to be implemented. In connection with the U.K.’s exit from the EU, the U.K. government is reviewing the regulatory framework of financial services companies. Certain changes have already been finalized, which have improved the solvency position of our U.K. business at September 30, 2024. Additionally, the remaining pending proposals may lead to future changes in the solvency position of our U.K. business.
The payment of dividends to the parent company from our subsidiaries also requires the approval of the individual subsidiary's board of directors.
During 2024, we intend to maintain a level of capital in our insurance subsidiaries above the applicable capital adequacy requirements and minimum solvency margins.
Insurance regulatory restrictions do not limit the amount of dividends available for distribution from non-insurance subsidiaries except where the non-insurance subsidiaries are held directly or indirectly by an insurance subsidiary and only indirectly by Unum Group, which does not apply to our current entity structure.
Funding for Employee Benefit Plans
During the nine months ended September 30, 2024, we made contributions of $59.6 million and £3.8 million to our U.S. and U.K. defined contribution plans, respectively, and expect to make additional contributions of approximately $18 million and £1 million during the remainder of 2024. We had no regulatory contribution requirements for our U.S. and U.K. qualified defined benefit pension plans and made no voluntary contributions during the nine months ended September 30, 2024. We do not expect to have regulatory contribution requirements for our U.S. and U.K. qualified defined benefit pension plans during the remainder of 2024, but we reserve the right to make voluntary contributions during the remainder of 2024. We have met all minimum pension funding requirements set forth by the Employee Retirement Income Security Act. We have estimated our future funding requirements under the Pension Protection Act of 2006 and under applicable U.K. law and do not believe that any future funding requirements will cause a material adverse effect on our liquidity. See Note 11 of the "Notes to Consolidated Financial Statements" of our annual report on Form 10-K for the year ended December 31, 2023 for further discussion.
Debt, Term Loan Facility, Credit Facilities and Other Sources of Liquidity
Our long-term debt balance at September 30, 2024 was $3,470.4 million, net of deferred debt issuance costs of $32.3 million, and is comprised of our unsecured senior notes, unsecured medium-term notes, and junior subordinated debt securities.
In June 2024, we issued $400.0 million of 6.000% senior notes due 2054. The notes are callable at or above par and rank equally in the right of payment with all of our other unsecured and unsubordinated debt. A portion of the net proceeds of the offering were used to repay the $350.0 million aggregate principal amount of outstanding indebtedness under our senior unsecured delayed draw term loan facility, which was terminated upon repayment. The remaining balance of the net proceeds is expected to be used for general corporate purposes.
During November 2021, we entered into a 20-year facility agreement with a Delaware statutory trust (the P-Caps Trust), in connection with the sale by the P-Caps Trust of $400.0 million of pre-capitalized trust securities (P-Caps) in a Rule 144A private placement. The P-Caps Trust invested the proceeds from the sale of the P-Caps in a portfolio of principal and interest strips of U.S. Treasury securities (the Trust Assets). The facility agreement gave us the right to issue and require the P-Caps Trust to purchase, on one or more occasions, up to $400.0 million of our 4.046% senior notes due 2041 (the 2041 Senior Notes) in exchange for the Trust Assets. Under the facility agreement, we agreed to pay a semi-annual facility fee to the P-Caps Trust at a rate of 2.225% per year on the unexercised portion of the maximum amount of 2041 senior notes that we could issue and sell to the P-Caps Trust and to reimburse the P-Caps Trust for its expenses.
In October 2024, we exercised our issuance right in full under the facility agreement and issued $400.0 million of the 2041 Senior Notes to the P-Caps Trust in exchange for the Trust Assets, thereby triggering our recognition of the 2041 Senior Notes on our consolidated balance sheets. The Trust Assets had a fair value of $273.5 million when the 2041 Senior Notes were issued. We directed the trustee of the P-Caps Trust to dissolve the P-Caps Trust and to deliver the 2041 Senior Notes to the beneficial holders of the P-Caps pro rata in respect of each P-Cap. The 2041 Senior Notes are callable at or above par and rank equally in the right of payment with all of our other unsecured and unsubordinated debt. The net proceeds from the issuance of the 2041 Senior Notes and subsequent sale of the Trust Assets are expected to be used for future share repurchases. See Note 14 of the "Notes to Consolidated Financial Statements" contained herein in Item 1.
We have a five-year $500 million senior unsecured revolving credit facility with a syndicate of lenders which is currently scheduled to expire in April 2027. We may request that the lenders’ aggregate commitments of $500.0 million under the facility be increased by up to an additional $200.0 million. Certain of our traditional U.S. life insurance subsidiaries may also borrow under the credit facility, subject to an unconditional guarantee by Unum Group. At September 30, 2024, there were no borrowed amounts outstanding under the revolving credit facility and letters of credit totaling $0.4 million had been issued.
We have a five-year £75 million senior unsecured standby letter of credit facility with a different syndicate of lenders, pursuant to which a syndicated letter of credit was issued in favor of Unum Limited (as beneficiary), our U.K. insurance subsidiary, and is available for drawings up to £75 million until its scheduled expiration in July 2026. We have an additional five-year, £75 million senior standby letter of credit facility pursuant to which a standby letter of credit was issued in favor of Unum Limited
(as beneficiary), our U.K. insurance subsidiary, and is available for drawings up to £75.0 million until its scheduled expiration in December 2028. In connection with and as security for the senior standby letter of credit facility, we granted to the issuer of the standby letter of credit the right to exercise, if an event of default occurred and was continuing, the issuance right under the facility agreement with the P-Caps Trust, up to a maximum of $200.0 million. In October 2024, prior to our exercise of the issuance right under the facility agreement, the assigned issuance right was forfeited in its entirety.
At September 30, 2024, no amounts have been borrowed under the standby credit facilities or letters of credit.
There are no significant financial covenants associated with any of our debt obligations other than our borrowings under the credit facilities, which are subject to financial covenants, negative covenants, and events of default that are customary. Each credit facility includes financial covenants based on our leverage ratio and consolidated net worth as well as covenants that limit subsidiary indebtedness. We continually monitor our debt covenants to ensure we remain in compliance. We have not observed any current trends that would cause a breach of any debt covenants.
See "Debt, Term Loan Facility, Credit Facilities and Other Sources of Liquidity" and Note 10 of the "Notes to Consolidated Financial Statements" contained in Part II, Items 7 and 8, respectively, of our annual report on Form 10-K for the year ended December 31, 2023 for further discussion.
Shelf Registration
We maintain a shelf registration with the Securities and Exchange Commission to issue various types of securities, including common stock, preferred stock, debt securities, depository shares, stock purchase contracts, units and warrants. The shelf registration enables us to raise funds from the offering of any securities covered by the shelf registration as well as any combination thereof, subject to market conditions and our capital needs.
Commitments
As of September 30, 2024, we had commitments of $38.0 million to fund investments in private placement fixed maturity securities and $805.6 million to fund private equity partnerships. In addition, we had $28.5 million of commercial mortgage loan commitments.
With respect to our commitments and off-balance sheet arrangements, see the discussion under "Cash Requirements" in Part II, Item 7 of our annual report on Form 10-K for the year ended December 31, 2023. During the first nine months of 2024, there were no substantive changes in our commitments, contractual obligations, or other off-balance sheet arrangements other than the changes noted herein.
Transfers of Financial Assets
Our investment policy permits us to lend fixed maturity securities to unaffiliated financial institutions in short-term securities lending agreements, which increases our investment income with minimal risk. We account for all of our securities lending agreements and repurchase agreements as secured borrowings. As of September 30, 2024, we held $25.8 million of cash collateral from securities lending agreements. The average cash collateral balance during the first nine months of 2024 was $46.2 million, and the maximum amount outstanding at any month end was $133.0 million. As of September 30, 2024, we held $34.4 million of off-balance sheet securities lending agreements which were collateralized by securities that we were neither permitted to sell nor control. The average balance of these off-balance sheet transactions during the first nine months of 2024 was $27.9 million, and the maximum amount outstanding at any month end was $38.6 million.
To manage our cash position more efficiently, we may enter into securities repurchase agreements with unaffiliated financial institutions. We generally use securities repurchase agreements as a means to finance the purchase of invested assets or for short-term general business purposes until projected cash flows become available from our operations or existing investments. We had no securities repurchase agreements outstanding at September 30, 2024, nor did we utilize any securities repurchase agreements during the first nine months of 2024. Our use of securities repurchase agreements and securities lending agreements can fluctuate during any given period and will depend on our liquidity position, the availability of long-term investments that meet our purchasing criteria, and our general business needs.
Certain of our U.S. insurance subsidiaries are members of regional FHLBs. As of September 30, 2024, we owned $25.6 million of FHLB common stock and had outstanding advances of $299.0 million from the regional FHLBs which were used for the purpose of investing in fixed maturity securities. As of September 30, 2024, we have additional borrowing capacity of approximately $642.1 million from the FHLBs.
See Note 4 of the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further information.
Consolidated Cash Flows
(in millions of dollars)
| Nine Months Ended September 30 2024 | 2023 | |
|---|---|---|
| Net Cash Provided by Operating Activities | $1,027.4 | $859.3 |
| Net Cash Used by Investing Activities | (393.1) | (498.6) |
| Net Cash Used by Financing Activities | (616.9) | (314.0) |
| Net Increase in Cash and Bank Deposits | $17.4 | $46.7 |
Operating Cash Flows
Operating cash flows are primarily attributable to the receipt of premium and investment income, offset by payments of claims, commissions, expenses, and income taxes. Premium income growth is dependent not only on new sales, but on policy renewals and growth of existing business, renewal price increases, and persistency. Investment income growth is dependent on the growth in the underlying assets supporting our insurance liabilities and capital and on the earned yield. The level of commissions and operating expenses is attributable to the level of sales and the first year acquisition expenses associated with new business as well as the maintenance of existing business. The level of paid claims is affected partially by the growth and aging of the block of business and also by the general economy, as previously discussed in the operating results by segment.
Investing Cash Flows
Investing cash inflows consist primarily of the proceeds from the sales and maturities of investments. Investing cash outflows consist primarily of payments for purchases of investments. Our investment strategy is to match the cash flows and durations of our assets with the cash flows and durations of our liabilities to meet the funding requirements of our business. When market opportunities arise, we may sell selected securities and reinvest the proceeds to improve the yield and credit quality of our portfolio. We may at times also sell selected securities and reinvest the proceeds to improve the duration matching of our assets and liabilities and/or re-balance our portfolio. As a result, sales before maturity may vary from period to period. The sale and purchase of short-term investments is influenced by proceeds received from FHLB funding advances, issuance of debt, our securities lending program, and by the amount of cash which is at times held in short-term investments to facilitate the availability of cash to fund the purchase of appropriate long-term investments, repay maturing debt, and/or to fund our capital deployment program.
During the third quarter of 2023, we sold over $700.0 million of shorter duration bonds in our long-term care portfolio and reinvested the proceeds in higher quality, higher yielding, and longer duration bonds that better match our liability cash flows. As a result of this activity, both sales and purchases of fixed maturity securities were lower in the first nine months of 2024 compared to the same period of 2023.
See Note 4 of the "Notes to Consolidated Financial Statements" contained herein in Item 1 for further information.
Financing Cash Flows
Financing cash flows consist primarily of borrowings and repayments of debt, dividends paid to stockholders, repurchases of common stock, and policyholders' account deposits and withdrawals.
Cash used to repurchase shares of Unum Group's common stock during the first nine months of 2024 and 2023 was $500.0 million and $174.2 million, respectively. In connection with the repurchases made during the first nine months of 2024 and 2023, we recognized $4.8 million and $1.2 million, respectively, of excise tax which has not been settled as of September 30, 2024. During the first nine months of 2024 and 2023, we paid dividends of $219.3 million and $205.7 million, respectively, to holders of Unum Group's common stock.
Also included in financing cash flows during the first nine months of 2024 and 2023 was $26.7 million and $18.6 million, respectively, of cash received related to the active life cohort volatility agreement with Commonwealth as a result of the Closed Block individual disability reinsurance transaction.
In June 2024, we issued $400.0 million of 6.000% senior notes due 2054 and received proceeds of $391.6 million. A portion of the net proceeds of the offering were used to repay the outstanding indebtedness under our senior unsecured delayed draw term loan facility, resulting in a cash outflow of $350.0 million.
Ratings
AM Best, Fitch Ratings (Fitch), Moody's Investors Service (Moody's), and Standard & Poor's Rating Services (S&P) are among the third parties that assign issuer credit ratings to Unum Group and financial strength ratings to our insurance subsidiaries. Issuer credit ratings reflect an agency's opinion of the overall financial capacity of a company to meet its senior debt obligations. Financial strength ratings are specific to each individual insurance subsidiary and reflect each rating agency's view of the overall financial strength (capital levels, earnings, growth, investments, business mix, operating performance, and market position) of the insuring entity and its ability to meet its obligations to policyholders. Both the issuer credit ratings and financial strength ratings incorporate quantitative and qualitative analyses by rating agencies and are routinely reviewed and updated on an ongoing basis.
We compete based in part on the financial strength ratings provided by rating agencies. A downgrade of our financial strength ratings can be expected to adversely affect us and could potentially, among other things, adversely affect our relationships with distributors of our products and services and retention of our sales force, negatively impact persistency and new sales, particularly large case group sales and individual sales, and generally adversely affect our ability to compete. A downgrade in the issuer credit rating assigned to Unum Group can be expected to adversely affect our cost of capital or our ability to raise additional capital.
The table below reflects the outlook as well as the senior unsecured debt ratings for Unum Group and the financial strength ratings for each of our traditional insurance subsidiaries as of the date of this filing.
| AM Best | Fitch | Moody's | S&P | |
| Outlooks | Stable | Positive | Stable | Stable |
| Senior Unsecured Debt Ratings | bbb+ | BBB | Baa2 | BBB |
| Financial Strength Ratings | ||||
| Provident Life and Accident Insurance Company | A | A | A2 | A |
| Unum Life Insurance Company of America | A | A | A2 | A |
| First Unum Life Insurance Company | A | A | A2 | A |
| Colonial Life & Accident Insurance Company | A | A | A2 | A |
| The Paul Revere Life Insurance Company | A | A | A2 | A |
| Unum Insurance Company | A | A | A2 | NR |
| Provident Life and Casualty Insurance Company | A | A | NR | NR |
| Starmount Life Insurance Company | A | NR | NR | NR |
| Unum Limited | NR | NR | NR | A- |
NR = not rated
We maintain an ongoing dialogue with the four rating agencies that evaluate us in order to inform them of progress we are making regarding our strategic objectives and financial plans as well as other pertinent issues. A significant component of our communications involves our annual review meeting with each of the four agencies. We hold other meetings throughout the year regarding our business, including, but not limited to, quarterly updates.
In May 2024, Moody's upgraded its senior unsecured debt ratings to Baa2 from Baa3 and also upgraded its financial strength ratings of our rated domestic insurance subsidiaries to A2 from A3. The ratings upgrade reflects strong capital levels, a reduction in asset risk, increasing profitability in the core business, and an improved long-term care position.
In September 2024, Fitch revised its outlook to positive from stable. The revision reflects strong capital and liquidity positions, sustained levels of improved profitability, and actions taken to mitigate risk in long-term care.
There have been no other changes in the rating agencies' outlooks or ratings during 2024 prior to the date of this filing.
Agency ratings are not directed toward the holders of our securities and are not recommendations to buy, sell, or hold our securities. Each rating is subject to revision or withdrawal at any time by the assigning rating organization, and each rating should be regarded as an independent assessment, not conditional on any other rating. Given the dynamic nature of the ratings process, changes by these or other rating agencies may or may not occur in the near-term. We have ongoing dialogue with the rating agencies concerning our insurance risk profile, our financial flexibility, our operating performance, and the quality of our investment portfolios. The rating agencies provide specific criteria and, depending on our performance relative to the criteria, will determine future negative or positive rating agency actions.
See our annual report on Form 10-K for the year ended December 31, 2023 for further information regarding our debt, issuer credit ratings and financial strength ratings and the risks associated with rating changes.
Market risk
As filed, 437 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are subject to various market risk exposures including interest rate risk and foreign exchange rate risk. With respect to our exposure to market risk, see the discussion under "Investments" in Item 2 of this Form 10-Q and in Part II, Item 7A of our annual report on Form 10-K for the year ended December 31, 2023. During the first nine months of 2024, there was no substantive change to our market risk or the management of this risk.
Controls and procedures
As filed, 977 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. We evaluated those controls based on the 2013 Internal Control - Integrated Framework from the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, these officers concluded that our disclosure controls and procedures were effective as of September 30, 2024.
There have been no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended, during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 139 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes from the risk factors disclosed in our annual report on Form 10-K for the year ended December 31, 2023.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $3.22bn | us-gaap:Revenues |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $9.65bn | us-gaap:Revenues |
| Operating income | 3 months2024-07-01 to 2024-09-30 | $501.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | $1.54bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $168.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $375.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | $645.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | $1.43bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | $3.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | $7.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | $3.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | $7.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 186,882,400 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 190,209,700 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | $1.03bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $93.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2024-01-01 to 2024-09-30 | $219.3m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2024-01-01 to 2024-09-30 | $500.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-30 | $163.4m | us-gaap:Cash |
| Total assets | At period end2024-09-30 | $64.14bn | us-gaap:Assets |
| Total liabilities | At period end2024-09-30 | $53.19bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | $10.95bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000005513-24-000161. Last ingested by Listed: Oct 24, 2026, 14:51 ET. Listed shows no prices and gives no investment advice.